

Mfg. of : Bulk Drugs, Drug Intermediates & Speciality Chemicals

Date: 28th August, 2021

To, The Manager BSE Ltd. Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400 001 BSE Scrip Code : 540359

Dear Sirs,

Reg.: Submission of Annual Report for Financial Year 2020-21 and AGM Notice for the 27th Annual General Meeting of the Company to be held on 20th September, 2021

Pursuant to Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations)', please find attached soft copy of the Annual Report for the Financial Year 2020-21 along with Notice for the 27th Annual General Meeting of members of Company to be held on Monday, 20th September, 2021 at 2.00 P.M.

Thanking you,

Yours faithfully,

For PARMAX PHARMA LIMITED

Yab

YASH VORA Company Secretary

Encl : As above

Copy to: Purva Sharegistry India Private Limited 9, Shiv Shakti Ind. Estt., J .R. Boricha marg, Lower Parel (E), Mumbai

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 Fax : +91-2827-270536 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504



Content

Corporate Information	01
Managing Director's Message	02
Notice of AGM	03
Directors' Report	19
Management Discussion and Analysis	25
Annexure to Directors' Report	28
Report on Corporate Governance	35
Independent Auditors Report	47
Audited Financial Statements	54

Parmax Pharma Limited

27th Annual Report 2020-21

Corporate Information

Board of Directors:

Dr. Umang A. Gosalia -		Managing Director (w.e.f. 29 th June 2021)
Mrs. Asha S. Daftary	-	Independent Director
Mr. Pramay A. Chhatra	-	Independent Director
Ms. Ami R. Shah	-	Independent Director

Key Managerial Personnel : Mr. Yash J. Vora (CS and Compliance Officer) Mr. Keyur D. Vora (Chief Financial Officer)

Statutory Auditors: B A Shah S R Mehta & Co., **Chartered Accountants** Rajkot

Bankers:

- _ HDFC Bank
- Kotak Mahindra Bank -
- **ICICI Bank**

Registered Office & Works: Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Rajkot - 360311, Gujarat Contact Number: 02827 – 270 534 / 270 535 Email: - info@parmaxpharma.com Website: - www.parmaxpharma.com

Registrar and Transfer Agent: Purva Sharegistry (India) Pvt. Ltd., Unit no. 9, Shiv Shakti Ind. Estate, J. R. Boricha Marg, Opp. Kasturba Hospital Lane, Lower Parel (E), Mumbai - 400 011

27th Annual General Meeting On Monday, 20th September, 2021 at 02:00 p.m. Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Rajkot

360311

Dr. Umang Gosalia Managing Director's Message

Dear Shareholders,

Please allow me to begin by paying tribute to Late Shri Alkesh Gosalia, our legendary and visionary Managing Director who was the helm of affairs of the Company for almost one and half decade. I strongly believe that the rich legacy left behind by him and the strong work culture embedded with deep familial values that he built during his tenure, will keep inspiring us and give us enough resilience to bounce back from any adversity in future.

Also, I wish to take this opportunity to express my sincere gratitude to Board Members for appointing me to the position left vacant by the untimely demise of Shri Alkesh Gosalia.

For the Company through the year, the top priority was to ensure the wellbeing of our employees. It is our belief that a high performing organisation is defined by empathetic management of people and talent. It is this unwavering commitment to the 'People First' philosophy and this value at the core of all our business strategy, which has helped Company to overcome the two waves of pandemic. The leadership remained committed to this employee centric vision even during pandemic; This fundamental value has also inspired business resilience.

Despite the challenging economic environment your Company delivered Gross Sales of Rs. 26.29 Crore in the fiscal year 2020-21, with increase of ~ 25%. as compared to last year. Overall, the business was impacted by Covid-19 induced lockdowns and restrictions during the year, but we continue to remain fully committed to creating long term value for our shareholders.

Finally, I am very proud of how the Parmax leadership team has stayed focused on the business and together delivered a relatively stable financial and operational performance this year. I would like to again acknowledge the efforts of each and every one of our team members for their adaptability, resilience and contribution during an exceptionally difficult year.

Lastly, I would like to thank all our business partners and shareholders for their continued support. With our clear strategic direction, Parmax is well positioned to drive profitable growth in the coming years.

Warm regards, Umang Gosalia

Parmax Pharma Limited

Plot no. 20, Survey no. 52, Rajkot- Gondal national highway no.27, Hadamtala, Rajkot-360311, Gujarat, India Tel: +912827 270534/35 Email: info@parmaxpharma.com Website: www.parmaxpharma.com

NOTICE

Notice is hereby given that the 27th Annual General Meeting of the members of Parmax Pharma Limited will be held on Monday 20th day of September, 2021, at 2.00 p.m. at the Registered office of the Company situated at Plot no. 20, survey no. 52, Rajkot-Gondal National Highway no. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot – 360 311 Gujarat.

Ordinary Business:

- To receive, consider and adopt the Audited Balance Sheet as at 31st March 2021, the Audited Statement of Profit and Loss for the year ended on that date and the Reports of the Directors' and Auditors' thereon.
- 2. To appoint a Director in place of Dr. Umang Alkesh Gosalia (DIN: 05153830) who retires by rotation and, being eligible, offers himself for re-appointment.

Special Business:

As an Ordinary Resolution:

3. To Consider change in designation and appointment of Dr. Umang Gosalia (DIN: 05153830) to be a Managing Director from the Whole-time Director of the Company for a period of 5 years and revision in remuneration payable to him.

To consider and if thought fit, to pass, with or without modification(s), the following resolution as Special Resolution:

"RESOLVED THAT in partial modification of the earlier resolution approved by the shareholders in its meeting held on 27th September, 2019, Mr. Umang Alkesh Gosalia (DIN: 05153830), who was appointed as Whole-time Director for a period of five years from 14th February, 2019 to 13th February, 2024, be and is hereby re-designated as Managing Director of the Company, effective from 29th June, 2021 for a period of 5 years.

RESOLVED FURTHER THAT the payment of remuneration amounting to Rs. 39 lakhs per annum to Mr. Umang Alkesh Gosalia, as Managing Director of the company with effect from 1st July, 2021.

RESOLVED FURTHER THAT the Ministry of Corporate Affairs (MCA) through its notification dated 12th September 2018 under notified provisions of the Companies (Amendment) Act, 2017 (Amendment Act, 2017) and amended schedule V of Companies Act, 2013. Respectively to the same, the Central Government amends Schedule V of Companies Act, 2013 vide Notification dated 12th September, 2018 and amends Part I and Part II related to conditions to be fulfilled for the Appointments and Remuneration

of a Managing or Whole-time director or a Manager without the approval of the Central Government but by the approval of members in the general meeting via special resolution.

RESOLVED FURTHER THAT the Board of Directors and the Nomination & Remuneration Committee be and is hereby authorised to vary such terms of appointment & remuneration specified above from time to time to the extent the Board of Directors may deem appropriate, provided that such variation, as the case may be, as specified under the relevant provisions of the Companies Act, 2013 and/or Schedule V.

RESOLVED FURTHER THAT in the event in any financial year during the tenure of the Managing Director, the Company does not earn any profits or earns inadequate profits as contemplated under the provisions of Schedule V to the Companies Act, 2013, the Company may pay to the Managing Director, the above remuneration excluding commission amount payable on the minimum remuneration by way of salary, Perquisites and Other terms & Conditions as specified above and subject to receipt of the requisite approvals.

RESOLVED FURTHER THAT If director draws or receives, directly or indirectly, by way of remuneration any such sums in excess prescribed by this section or without approval required under this section, he shall refund such sums to the company, within two years or such lesser period as may be allowed by the company, and until such sum is refunded, hold it in trust for the company. The company shall not waive the recovery of any sum refundable to it unless approved by the company by special resolution within two years from the date the sum becomes refundable and in accordance with the provisions of Schedule V of the Companies Act 2013.

"RESOLVED FURTHER THAT for the purpose of giving effect to this resolution, any Director and Company Secretary of the Company be and is hereby authorised to do all such acts, deeds, matters and things as they may in their absolute discretion deem necessary, expedient, usual and proper in the best interest of the Company."

As Special Resolution

4. To re-appointment of and continuation of Directorship of Mrs. Asha Daftary as an Independent Director of the Company for a second term of 5 years.

To consider and if thought fit, to pass, with or without modification(s), the following resolution as an Special Resolution :

"RESOLVED THAT pursuant to the provisions of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and Sections 149, 150, 152, 197 read with Companies (Appointment and Qualification of Directors) Rules, 2014 and other applicable provisions of the Companies Act, 2013 and the rules made thereunder (including any statutory modification(s) or re-enactment thereof for the time being in force) read with Schedule IV to the Companies Act, 2013, the approval of the members/shareholders of the Company be and are hereby accorded to the Re-appointment of Mrs. Asha Daftary (DIN : 07433167) as an 'Independent Director' (Non-Executive) on the Board of the Company for a period of five consecutive years from 10.02.2021 to 09.02.2026 as recommend/ approved by the Nomination & Remuneration Committee and Board of Directors in its meeting held on February 12, 2021.

"RESOLVED FURTHER THAT pursuant to the provisions of sections 149, 197 and other applicable provisions of the Companies Act 2013 and the rules made thereunder (Including any statutory modification(s) or re-enactment thereof for the time being in force), Mrs. Asha Daftary be paid such fees as the Board may approve from time to time and subject to such limits, prescribed or as may be prescribed by the Company from time to time."

As Special Resolution

5. To re-appointment of Mr. Pramay Chhatra as an Independent Director of the Company for a second term of 5 years.

To consider and if thought fit, to pass, with or without modification(s), the following resolution as an Special Resolution :

"RESOLVED THAT pursuant to the provisions of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and Sections 149, 150, 152, 197 read with Companies (Appointment and Qualification of Directors) Rules, 2014 and other applicable provisions of the Companies Act, 2013 and the rules made thereunder (including any statutory modification(s) or re-enactment thereof for the time being in force) read with Schedule IV to the Companies Act, 2013, the approval of the members/shareholders of the Company be and are hereby accorded to the Re-appointment of Mr. Pramay Chhatra (DIN : 07437291) as an 'Independent Director' (Non-Executive) on the Board of the Company for a period of five consecutive years from 13.02.2021 to 12.02.2026 as recommend/ approved by the Nomination & Remuneration Committee and Board of Directors in its meeting held on February 12, 2021.

"RESOLVED FURTHER THAT pursuant to the provisions of sections 149, 197 and other applicable provisions of the Companies Act 2013 and the rules made thereunder (Including any statutory modification(s) or re-enactment thereof for the time being in force), Mr. Pramay Chhatra be paid such fees as the Board may approve from time to time and subject to such limits, prescribed or as may be prescribed by the Company from time to time."

By order of the Board of Directors For Parmax Pharma Limited

Date: 14th August, 2021 Place: Rajkot

Dr. Umang Gosalia Managing Director DIN: 05153830

Notes :

 A member entitled to attend and vote at the meeting is entitled to appoint a proxy to attend and vote instead of himself/herself and a proxy need not be a member. PROXY in form no. MGT-11 to be effective should reach the registered office of the company not less than 48 hours before the time fixed for the meeting. A person can act as a proxy on behalf of members not exceeding fifty and holding in the aggregate not more than ten percent of the total share capital of the

Company carrying voting rights. A member holding more than ten percent of the total share capital of the total share capital of the Company carrying voting rights may appoint a single person as proxy and such person shall not act as a proxy for any other person or shareholder.

- Proxies, in order to be effective, should be duly stamped, completed, signed and deposited at the Registered Office of the Company not less than 48 hours before the meeting. A Proxy form is sent herewith. Proxies submitted on behalf of the companies, societies etc., must be supported by an appropriate resolution/authority, as applicable.
- 3. The Register of Members and Share Transfer Books of the Company will remain closed from Tuesday, 14th September, 2021 to Monday, 20th September, 2020 (both days inclusive) for the purpose of Annual General Meeting of the Company.
- 4. The members are requested to intimate their change of address, if any, immediately to the Company & its Registrar And Transfer Agent (RTA) Viz. Purva Sharegistry (India) Pvt. Ltd., Unit no. 9, Shiv Shakti Ind. Estt., J.R. Boricha Marg, Opp. Kasturba Hospital Lane, Lower Parel (E), Mumbai-400 011 quoting their Folio No. or Client ID No.
- 5. Members desiring any information on Accounts are requested to write to the Company at least one week before the meeting so as to enable the management to keep the information ready. Replies will be provided at the meeting.
- 6. As a measure of economy, copies of Annual Report will not be distributed at the Annual General Meeting. Shareholders are requested to bring their copies of Annual Report and the attendance slip at the Annual General Meeting.
- 7. Nomination facility is available to the Share holders in respect of share held by them.
- 8. Members who hold shares in dematerialized form are requested to write their Client ID and DP ID numbers and those who hold shares in physical form are requested to write their Folio number in the attendance slip for attending the meeting.
- The relevant Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 and Secretarial Standards issued by the Institute of Company Secretaries of India (the 'ICSI') in respect of the special business under item numbers 3, 4 and 5 is annexed.
- 10. The Company has appointed Mr. Samsad Alam Khan (CP No.13972), Practising Company Secretaries and in absence of him, Mr. Amrish Gandhi, Proprietor of Amrish Gandhi & Associates, Practising Company Secretaries, who, in the opinion of the Board are duly qualified persons, as a Scrutinizer who will scrutinize the electronic voting process in a fair and transparent manner. The Scrutinizer shall within a period of 48 hours from the date of conclusion of the Meeting, submit his report of the votes cast in favour or against, if any, to the Chairman of the Company and the result of the same will be disclosed forthwith. The Company has appointed CDSL for the purpose of facilitating the electronic voting.
- Information relating to the Directors proposed to be appointed and those retiring by rotation and seeking re-appointment at this Meeting, as required under Regulation 36(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is annexed to this Notice.

i			
Name	Umang A. Gosalia	Asha Daftary	Pramay Chhatra
Date of Birth	23/04/1984	21/02/1949	19/08/1958
DIN	05173830	07433167	07437291
No. of Equity Shares held in the Company	1,00,000	NIL	NIL
Relationship with other Directors/ Manager /KMP	None	None	None
Education Qualification	M.Sc. and Doctorate in Organic (Chemistry)	Bachelor Degree in Arts.	Bachelor Degree in Science.
Profile & Expertise in Specific functional Areas	Ph.D. (Doctorate in Organic (Chemistry) and having experience over a decade in chemistry & various types of organic reactions, and currently looking after the all production activities of the Company.	Having experience over a decade in general administration.	Having experience over a decade in general administration and science and technologies.
List of other Directorship / Committee membership in other Companies as on 31 st March, 2021.	None	None	None
Original date of appointment	02.01.2016	10.02.2016	12.02.2016

12. Electronic copy of the Annual Report for 2020-21 is being sent to all the members whose email IDs are registered with the Company/Depository Participants(s) for communication purposes unless any member has requested for a hard copy of the same.

13. Voting through electronic means:

The Company is pleased to offer e-voting facility to all its members to enable them to cast their vote electronically in terms of Section 108 of the Companies Act, 2013 read with the Companies (Management and Administration) Rules, 2014 and Regulation 44 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (including any statutory modification or re-enactment thereof for the time being in force). Accordingly, a member may exercise his vote by electronic means and the Company may pass any resolution by electronic voting system in accordance with the above provisions.

THE INTRUCTIONS OF SHAREHOLDERS FOR REMOTE E-VOTING ARE AS UNDER:

(i) The voting period begins on 17th September, 2021 9.00 AM IST and ends on 19TH September, 2021 5.00 PM IST During this period shareholders' of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date (13TH September, 2021) of 14th September, 2021 may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.

- (ii) Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.
- (iii) Pursuant to SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09.12.2020, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

(iv) In terms of SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to above said SEBI Circular, Login method for e-Voting and joining virtual meetings for Individual shareholders holding securities in Demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in Demat mode with CDSL	Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest are https://web.cdslindia.com/myeasi/home/login or visit www.cdslindia.com and click on Login icon and select New System Myeasi. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service
	Providers i.e. CDSL/NSDL/KARVY/LINKINTIME, so that the user can visit the e-Voting service providers' website directly. If the user is not registered for Easi/Easiest, option to register is available at https://web.cdslindia.com/myeasi/Registration/EasiRegistration.
	Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the e-voting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Shareholders holding securities in demat mode with NSDL	If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: https://eservices.nsdl.com either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.
	If the user is not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select "Register Online for IDeAS "Portal or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp
	Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting
Individual Shareholders (holding securities in	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on

demat mode)	company name or e-Voting service provider name and you will be redirected to e-Voting service
login through	provider website for casting your vote during the remote e-Voting period or joining virtual meeting &
their	voting during the meeting.
Depository	
Participants	

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.comor contact at 022- 23058738 and 22-23058542-43.
Individual Shareholders holding securities in Demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 1800 1020 990 and 1800 22 44 30

(v) Login method for e-Voting and for shareholders other than individual shareholders holding in Demat form & physical shareholders.

- 1) The shareholders should log on to the e-voting website <u>www.evotingindia.com</u>.
- 2) Click on "Shareholders" module.
- 3) Now enter your User ID
 - a. For CDSL: 16 digits beneficiary ID,
 - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
 - c. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.
- 4) Next enter the Image Verification as displayed and Click on Login.
- 5) If you are holding shares in demat form and had logged on to <u>www.evotingindia.com</u> and voted on an earlier e-voting of any company, then your existing password is to be used.
- 6) If you are a first-time user follow the steps given below:

	For Shareholders holding shares in Demat Form other than individual and Physical Form
PAN	Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.
Dividend Bank Details OR Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login.

	If both the details are not recorded with the depository or company,
	please enter the member id / folio number in the Dividend Bank details
	field as mentioned in instruction (v).

- (vi) After entering these details appropriately, click on "SUBMIT" tab.
- (vii) Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- (viii) For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- (ix) Click on the EVSN for the relevant <Company Name> on which you choose to vote.
- (x) On the voting page, you will see "RESOLUTION DESCRIPTION" and against the same the option "YES/NO" for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- (xi) Click on the "RESOLUTIONS FILE LINK" if you wish to view the entire Resolution details.
- (xii) After selecting the resolution, you have decided to vote on, click on "SUBMIT". A confirmation box will be displayed. If you wish to confirm your vote, click on "OK", else to change your vote, click on "CANCEL" and accordingly modify your vote.
- (xiii) Once you "CONFIRM" your vote on the resolution, you will not be allowed to modify your vote.
- (xiv) You can also take a print of the votes cast by clicking on "Click here to print" option on the Voting page.
- (xv) If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.

(xvi) Facility for Non – Individual Shareholders and Custodians –Remote Voting

- Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to <u>www.evotingindia.com</u> and register themselves in the "Corporates" module.
- A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to <u>helpdesk.evoting@cdslindia.com</u>.
- After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
- The list of accounts linked in the login should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.
- A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
- Alternatively Non Individual shareholders are required to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz; cs@parmaxpharma.com (designated email address by company) , if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/DEPOSITORIES.

- 1. For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to Company/RTA email id.
- 2. For Demat shareholders -, Please update your email id & mobile no. with your respective Depository Participant (DP)
- 3. For Individual Demat shareholders Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository.

If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting System, you can write an email to <u>helpdesk.evoting@cdslindia.com</u> or contact at 022- 23058738 and 022-23058542/43.

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Sr. Manager, (CDSL,) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call on 022-23058542/43.

CONTACT DETAILS	
Company	Parmax Pharma Limited Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot – 360 311
Registrar and Transfer Agent	M/s. Purva Sharegistry (India) Pvt. Ltd. Unit no. 9, Shiv Shakti Ind. Estt. J .R. Boricha Marg, Opp. Kasturba Hospital Lane, Lower Parel (E), Mumbai 400 011
e-voting Agency	Central Depository Services (India) Limited E-mail: <u>helpdesk.evoting@cdslindia.com</u>
Scrutinizer	CS Samsad Alam Khan / CS Amrish Gandhi Practicing Company Secretary Email:admin@agskcs.com,amrishgandhi72@gmail.com Ph: 079-40323014

EXPLANATORY STATEMENT IN RESPECT OF THE SPECIAL BUSINESS PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013.

Item No. 3

The shareholders vide special resolution passed in its meeting held on 27th September, 2019 approved the change in designation and appointment of Dr. Umang Gosalia as Whole-time Director of the Company for a period of five years w.e.f. 14th February, 2019.

The terms and conditions of his appointment, including remuneration were approved by the shareholders in accordance with the provisions contained in Sections 196, 197, 203 read with Schedule V and all other applicable provisions of the Companies Act, 2013.

The Board of Directors at their meeting held on 11th May, 2021 noted the cessation of Shri Alkesh Gosalia from the post of Managing Director due to demise and Board Meeting dated 29th June, 2021, The Board of Directors were in opinion to change in designation of Mr. Umang Gosalia and appoint him as the Managing Director from Whole-time Director of the Company and it will be beneficial to the Company.

Pursuant to the recommendation by the Nomination and Remuneration Committee, the Board of Directors at their meeting held on 29th June, 2021, has re-designated Dr. Umang Gosalia as Managing Director of the Company for a period of 5 years w.e.f. 29th June, 2021.

The information in respect of terms of remuneration & perquisites is given below:

Revised terms of Remuneration, benefits and perquisites:

- I. Salary of Rs. 3,25,000/- (Three lakh twenty five thousand) per month, and will entitled to general increment depending on his performance. Salary will be subject to the deduction of Income tax/professional tax at the applicable rates, under the Income Tax Act, 1961.
- II. Limits on Remuneration:

The remuneration as specified in clauses above shall be subject to the overall limits as specified under Sections 196, 197 and other applicable provisions read with Schedule V of the Companies Act, 2013.

- III. Minimum Remuneration:
 In the event of the Company incurring a loss or having inadequate profits in any financial year, the remuneration, perquisites, benefits, allowances and amenities payable to Dr. Umang Gosalia shall be in accordance with Section II of Part II of Schedule V of the Companies Act, 2013 as amended from time to time.
- IV. He shall not be paid sitting fees for attending the meetings of the Board of Directors of the Company and committees thereof.

Dr. Umang Gosalia will be liable to retire by rotation during his tenure as Managing Director.

Dr. Umang Gosalia is holding 100000 Equity shares consisting 2.67% of the paid up capital of the Company.

This explanation, together with the accompanied notice is and should be treated as an abstract under Section 189 and 190 of the Companies Act, 2013 and rules made there under, in respect of the appointment of Dr. Umang Gosalia, as the Managing Director.

The resolution for seeks approval of members as an Special Resolution for the change in designation and appointment of Dr. Umang Gosalia as Managing Director of the Company with retrospective effect from 29th June 2021 to 28th June, 2026, pursuant to the provisions of Section 196 and 197 read with Schedule V other applicable provision of the Companies Act, 2013 and the rules made there under.

Item No. 4

Mrs. Asha Daftary is associated with the Company as an Independent Director since year 2016 and she is possessing rich and vast experience in field of General Administration. In the Opinion of the Board, Mrs. Asha Daftary, the Independent Director proposed to be appointed, fulfils the conditions specified in the Act and rules made thereunder and she is independent of the management A copy of draft letter for the re-appointment of Mrs. Asha Daftary, as an Independent Director setting out the terms and conditions is available for inspection without any fee by the members, at the company's Registered office during normal business hours on working day upto the date of AGM. The Board considers that his continued association would be immense benefit to the company and it is desirable to continue to avail the services of Mrs. Asha Daftary as an Independent Director. Accordingly, the Board recommends the resolution to appoint Mrs. Asha Daftary as an Independent Director for the Approval of members. Except Mrs. Asha Daftary, being an appointee, none of the Directors and Key Managerial Personnel of the Company and their relatives is concerned or interested, financial or otherwise, in the resolution set out at Item No.4.

This Explanatory Statement may also be regarded as a disclosure under SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Mrs. Asha Daftary does not holding any Equity shares of the Company. This explanation, together with the accompanied notice is and should be treated as an abstract under Section 189 and 190 of the Companies Act, 2013 and rules made there under, in respect of the re-appointment of Mrs. Asha Daftary, as an Independent Director.

As the Mrs. Asha Daftary has attained the age of 72 years and during her consecutive tenure she will attend the age of 75 years hence as per the provisions of SEBI (LODR) Regulations, 2015 this resolution seeks approval of members as an Special Resolution for the re-appointment and continuation of Mrs. Asha Daftary as an Independent Director of the Company with effect from 10th February, 2021 pursuant to the provisions of Section 149, 150, 152, 197 read with Schedule IV and other applicable provision of the Companies Act, 2013 and the rules made there under.

<u>Item No. 5</u>

Mr. Pramay Chhatra is a Businessman and he is possessing rich and vast experience in field of General Administration, trading and Export and Import field. In the Opinion of the Board, Mr. Pramay Chhatra, the Independent Director proposed to be appointed, fulfils the conditions specified in the Act and rules made thereunder and she is independent of the management A copy of draft letter for the re-appointment of Mr. Pramay Chhatra, as an Independent Director setting out the terms and conditions is available for inspection without any fee by the members, at the company's Registered office during normal business hours on working day upto the date of AGM. The Board considers that his continued association would be immense benefit to the company and it is desirable to continue to avail the services of Mr. Pramay Chhatra as an Independent Director. Accordingly, the Board recommends the resolution to appoint Mr. Pramay Chhatra as an Independent Director for the Approval of members. Except Mr. Pramay Chhatra, being an appointee, none of the Directors and Key Managerial Personnel of the Company and their relatives is concerned or interested, financial or otherwise, in the resolution set out at Item No.5.

This Explanatory Statement may also be regarded as a disclosure under SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Mr. Pramay Chhatra does not holding Equity shares of the Company. This explanation, together with the accompanied notice is and should be treated as an abstract under Section 189 and 190 of the Companies Act, 2013 and rules made there under, in respect of the re-appointment of Mr. Pramay Chhatra, as an Independent Director.

Pursuant to provisions of SEBI (LODR) Regulations, 2015 this resolution seeks approval of members as an Special Resolution for the re-appointment of Mr. Pramay Chhatra as an Independent Director of the Company with effect from 13th February, 2021 pursuant to the provisions of Section 149, 150, 152, 197 read with Schedule IV and other applicable provision of the Companies Act, 2013 and the rules made there under.

By order of the Board of Directors For Parmax Pharma Limited

Date: 14th August, 2021 Place: Rajkot Dr. Umang Gosalia Managing Director DIN: 05153830

PARMAX PHARMA LIMITED

CIN: L24231GJ1994PLC023504 Registered Office: Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot – 360 311, Gujarat, India E-mail: <u>info@parmaxpharma.com</u>

Form No. MGT-11 Proxy form [Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]

Name of the Member(s)		
Registered Address		
E-mail Id	Folio No /Client ID	DP ID

I/We, being the member(s) of ______shares of the above named company. Hereby appoint

E-mail Id:

Name	:

Address:

Signature , or failing him

Name :	E-mail Id:
Address:	
Signature , or failing him	

Name :	E-mail Id:
Address:	
Signature , or failing him	

as my/ our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 27th Annual General Meeting of the company, to be held on the Monday 20th of September, 2021 at 02: 00 p.m. at PARMAX PHARMA LIMITED, Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot – 360 311, Gujarat, India and at any adjournment thereof in respect of such resolutions as are indicated below:-

Note:

1) This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company not less than 48 hours before the commencement of the Meeting.

2) The proxy need not be a member of the company

Resolutions to be passed at the Annual General Meeting:

SI. No.	Resolution(S)	Vo	ote
NO.		For	Against
1.	To receive, consider and adopt the Audited Balance Sheet as at 31st March 2021, the Audited Statement of Profit and Loss for the year ended on that date and the Reports of the Directors' and Auditors' thereon.		
2.	To appoint a Director in place of Dr. Umang Alkesh Gosalia (DIN: 05153830) who retires by rotation and, being eligible, offers himself for re-appointment.		
3.	To Consider change in designation and appointment of Dr. Umang Gosalia (DIN: 05153830) to be a Managing Director from the Whole-time Director of the Company for a period of 5 years and revision in remuneration payable to him.		
4.	To re-appointment of and continuation of Directorship of Mrs. Asha Daftary as an Independent Director of the Company for a second term of 5 years.		
5.	To re-appointment of Mr. Pramay Chhatra as an Independent Director of the Company for a second term of 5 years.		

Signed this _____day of _____2021

Signature of Shareholder

Affix Revenue Stamps

Signature of Proxy holder _____

Note:

- **1)** Members are requested to bring their copies of the Annual Report to the meeting, since further copies will not be available.
- **2)** The Proxy, to be effective should be deposited at the Registered Office of the Company not less than FORTY EIGHT HOURS before the commencement of the meeting.

- **3)** A Proxy need not be a member of the Company.
- **4)** In the case of joint holders, the vote of the senior who tenders a vote, whether in person or by Proxy, shall be accepted to the exclusion of the vote of the other joint holders. Seniority shall be determined by the order in which the names stand in the Register of Members.
- **5)** The submission by a member of this form of proxy will not preclude such member from attending in person and voting at the meeting.

Director's Report

Dear Shareholders,

The Board of Directors are pleased to present their 27th Annual Report on the business and operations of the Company and the Audited financial accounts for the Year ended 31st March, 2021.

Financial Results:

	(Rs. In la
For the year ended on 31 st March, 2021	For the year ended on 31 st March, 2020
2629.34	2103.19
2314.34	1929.41
315.00	173.78
194.16	100.71
0	0
0	0
120.84	73.07
75.44	42.87
136.73	
0	0
0	0
75.44	42.87
2.02*	1.15*
2.02*	1.15*
	on 31 st March, 2021 2629.34 2314.34 315.00 194.16 0 194.16 0 120.84 75.44 136.73 0 0 75.44 136.73 0 0 2000 2000 2000

*- Amount of EPS is in Rs.

Highlights of Performance:

The company has posted a satisfactory performance for the year under review. The total revenue of the Company has increased from Rs. 2103.19 lacs to Rs. 2629.34 lacs. The profit before tax of the Company has increased from Rs. 73.07 lacs to Rs. 120.84. The net profit after tax has increased from Rs. 42.87 lacs to Rs. 75.44 lacs. We remained resolute and relentless in our quest for strengthening our cost-competiveness, better management of working capital and operational excellence across all businesses.

Dividend:

Keeping in view the financial results and in order to conserve financial resources for the future requirement of the fund, your directors do not recommend any dividend during the year under review

Public Deposits:

The Company had accepted deposits of Rs. 25 Lakh from Relative of Directors and Promoters and hence the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the Companies (Acceptance of Deposit) Rules, 2015 with regard to the deposits accepted from the relative of Director contravenes.

Subsidiary/ Joint Venture/ Associate Company:

As on 31st March, 2021, Your Company has *Nil* Subsidiary/Joint Venture/ Associate Company.

INTERNAL CONTROL SYSTEMS

Your Company has a robust system of internal controls commensurate with the size of the Company and the nature of its business, which ensures that transactions are recorded, authorised and reported correctly apart from safeguarding its assets against loss from wastage, unauthorised use and disposition. The internal control systems are supplemented by well documented policies, guidelines and procedures which are in line with the internal financial control framework requirements. There is an extensive programme of internal audit by a firm of chartered accountants followed by periodic management reviews. The Audit Committee actively reviews the adequacy and effectiveness of the internal control systems and suggests improvements to strengthen the same.

RISK MANAGEMENT

Your Company considers that risk is an integral part of its business and therefore, it takes proper steps to manage all risks in a proactive and efficient manner. The Company management periodically assesses risks in the internal and external environment and incorporates suitable risk treatment processes in its strategy and business and operating plans. The details of practices being followed by the Company in this regard, form part of the Corporate Governance Report. There are no risks which, in the opinion of the Board, threaten the very existence of your Company. However, some of the challenges faced by it have been dealt with under Management Discussion and Analysis which forms part of this Report.

Depository System:

As members are aware, the company's shares are compulsorily tradable in the electronic form. As on March 31, 2021 almost 66.69% of the Company's total paid-up capital representing 24,95,260 shares were in dematerialized form. In view of the numerous advantages offered by the Depository system, members holding shares in physical mode are advised to avail of the facility of dematerialization on either of the Depositories.

Sr.	Date on which board Meetings	Total Strength of	No. of Directors
No.	were held	the Board	Present
1	11.06.2020	7	4
2	31.07.2020	7	4
3	15.09.2020	7	5
4	12.11.2020	7	6
5	16.01.2021	7	6
6	12.02.2021	5	5

BOARD MEETINGS HELD DURING THE YEAR:

Attendance of Directors at Board Meetings:

Sr. No.	Name of Directors	No. of Meeting Held	No. of Meeting Attended		
1	Alkesh M Gopani	5	2		
2	Alkesh R Gosalia	6	6		
3	Umang A Gosalia	6	6		
4	Vipul Gopani	5	2		
5	Asha S Daftary	6	5		
6	Pramay A Chhatra	6	6		
7	Ami R. Shah	6	4		

DIRECTORS AND KEY MANAGERIAL PERSONNEL:

- In terms of Section 152 of the Companies Act, 2013, Mr. Umang Alkesh Gosalia (DIN: 005173830) is liable to retire by rotation at forthcoming AGM and being eligible offers himself for re-appointment.
- A brief resume of director being re-appointed with the nature of their expertise, their shareholding in the Company as stipulated under as required under Regulation 36(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is annexed to this Notice of the ensuing Annual General Meeting.
- The Company has received necessary declaration from each independent director under Section 149(7) of the Companies Act, 2013, that he/she meets the criteria of independence laid down in Section 149(6) of the Companies Act, 2013 and Regulation 16(1) (b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- All the directors of the Company have confirmed that they are not disqualified from being appointed as directors in terms of Section 164 of the Companies Act, 2013.

MATTERS AS PRESCRIBED UNDER SUB-SECTIONS (1) AND (3) OF SECTION 178 OF THE COMPANIES ACT 2013:

The policy of the Company on directors' appointment and remuneration, including criteria for determining qualifications, positive attributes, independence of a director and other matters provided under Sub section (3) of Section 178 of the Companies Act, 2013, adopted by the Committee, is appended in the Corporate Governance Report.

EXTRACT OF ANNUAL RETURN AS PER SECTION 92 (3) OF COMPANIES ACT, 2013:

The Annual Return as required under Section 92 and Section 134 of the Companies Act, 2013 read with Rule 12 of the Companies (Management and Administration) Rules, 2014 is available on the website of the Company and the web-link for the same is https://www.parmaxpharma.com/investor_relations.php

KEY FINANCIAL RATIOS:

Key Financial Ratios for the financial year 2020-21 with comparatives for the year 2019-20, are disclosed in 'Annexure – C'

BOARD EVALUATION:

Pursuant to the provisions of the Companies Act, 2013, the Board has carried out an annual evaluation of its own performance, the directors individually, as well as the evaluation of the working of its Committees. At the meeting of the Board all the relevant factors that are material for evaluating the performance of individual Directors, the Board and its various committees were discussed in detail. A structured questionnaire each for evaluation of the Board, its various Committees and individual Directors was prepared and recommended to the Board by Nomination & Remuneration Committee for doing the required evaluation after taking into consideration the input received from the Directors covering various aspects of the Board's functioning such as adequacy of the composition of the Board and its Committees, execution and performance of specific duties, obligations and governance etc.

AUDITORS:

Statutory Auditors

Company had appointed M/s B.A. Shah S.R. Mehta & Co., Chartered Accountants for the purpose of carrying out Statutory Audit of the Company.

Secretarial Auditor

Mr. Samsad Alam Khan, Practicing Company Secretaries is re-appointed to conduct the secretarial audit of the Company for the financial year 2020-21, as required under Section 204 of the Companies Act, 2013 and

Rules thereunder. Your Company has received consent from Mr. Samsad Alam Khan to act as the auditor for conducting audit of the Secretarial records for the financial year ending 31st March, 2022. The secretarial audit report for FY 2020-21 forms part of the Annual Report as **'Annexure B'** to the *Board's report*.

Directors Response to Secretarial Audit Report and Audit Report:-

Your Board of Directors would like to clarify the qualification remarks made in Secretarial Audit Report as under:-

	Qualification/ Adverse Remark	Explanation :
1.	Company has not complied with the provisions of Section 74 of the Companies Act, 2013 regarding acceptance of deposits.	 The Board is in process of complying with Section 74 of Companies Act, 2013 regarding Acceptance of deposits.
2.	100% Promoters' holding still not in Demat form, 700 Equity Shares of Mr. Mahasukh Gopani is not in dematerialized form.	 As confirmed by the Promoters that they are in process of Dematerialization of 700 shares and it will be completed in due course. However, Board assures to comply with the Act and Regulations.

Directors Response to Statutory Audit Report:-

Qualification/ Adverse Remark	Explanation :
The Company has accepted deposits of Rs. 25 Lakh from Relative of Directors and hence the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the Companies (Acceptance of Deposit) Rules, 2015 with regard to the deposits accepted from the relative of Director is contravening.	The Board is in process of complying with Section 74 of Companies Act, 2013 regarding Acceptance of deposits.
Company has not maintained the Fixed Asset Register	Company Management is in process of maintaining Fixed Asset Register.

• Internal Auditors:

The Board appointed M/s. B A Shah & Associates., Chartered Accountants (Firm Registration Number:- 109493W) hereby appointed as Internal Auditor of the company for the financial year 2020-21. The report prepared by the Internal Auditors is to be reviewed by the Statutory Auditors & Audit Committee.

• Internal Financial Control System and their Adequacy:

The details in respect of internal financial control and their adequacy are included in the Management Discussion & Analysis Report, which forms part of this report.

• Particulars of Loans, Guarantees or Investments under Section 186:

Details of Loans, Guarantees and Investments under the provisions of Section 186 of the Companies Act, 2013 are not applicable to the Company.

• Audit Committee:

The composition and the functions of the Audit Committee of the Board of Directors of the Company is disclosed in the Report on Corporate Governance, which is forming a part of this report.

• Related Party Transactions:

All the related party transactions entered into during the financial year were on an arm's length basis and were in the ordinary course of business. Accordingly, the disclosure of related party transactions as required under Section 134(3) (h) of the Companies Act, 2013 in Form AOC 2 is attached in "Annexure C".

• Significant and Material Orders passed by the Regulators or Courts:

During the year under review, on 20th August 2020, under section 133 of Criminal Procedure Code the Sub-divisional magistrate and Deputy Collector Rajkot Zone -2 has passed conditional order to shut down our production capacity till further notice and after our written representations the Sub-divisional magistrate and Deputy Collector Rajkot Zone -2 has passed final order to operate and carry out our production activities and withdraw its earlier conditional order on 14th September, 2020 other than this no significant and material order was passed by the Regulators/Courts that could impact the going concern status of the Company and its future operations.

There is no proceeding pending under the Insolvency and Bankruptcy Code, 2016. There was no instance of onetime settlement with any Bank or Financial Institution.

• Policy against Sexual Harassment at Workplace

The Company values the dignity of individuals and is committed to provide an environment, which is free of discrimination, intimidation and abuse. The Company has put in place a policy on redressal of Sexual Harassment and a Policy on redressal of Workplace Harassment as per the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 ("Sexual Harassment Act"). As per the policy, any employee may report his/ her complaint to the Redressal Committee formed for this purpose or their Manager or HR personnel. The company has also constituted an Internal Complaints Committee to inquire into complaints of sexual harassment and recommendation for appropriate action. No complaints have been filed/ disposed of/ pending during the financial year ended 31st March, 2021

• Material changes:

There are no material changes and commitments, that would affect financial position of the company from the end of the financial year of the company to which the financial statements relate and the date of the directors report.

Reserves:

The Company has proposed to transfer Rs.75,44,218/- profit of the Company to the General Reserve for this year.

• Employee Stock Option: The Company has not issued any Employee Stock Option.

• Cash Flow analysis:

The Cash Flow Statement for the year under reference in terms of Regulation 34(2) (c) of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 with the stock exchanges forms part of the Annual Report.

• Conservation of energy, research and development, technology absorption, foreign exchange earnings and outgo:

A) Conservation of Energy:

Your company is serious in conserving energy by reducing consumption of power by implementing closed monitoring over plan running and adequate maintenance of electric components of plants and other machinery. Company has not made any capital investment or not taken any other steps for conservation of energy or the clause is not applicable.

B) Technology absorption:

Your company has not made any efforts towards technology absorption and neither imported any technology nor made any expenditure on research and developments.

C) Foreign Exchange earnings and outgo:

Foreign Exchange inflow (Rs.): **NIL** Foreign Exchange outflow (Rs.): **37,74,000/-.**

• Corporate Governance:

The Company is committed to maximise the value for its stakeholders by adopting the principles of good Corporate Governance in line with the provisions of law and particularly those stipulated in the Listing Regulations. Its objective and that of its management and employees is to manufacture and market the Company's products in a way so as to create value that can be sustained over the long term for consumers, shareholders, employees, business partners and the national economy in general.

Certificate from the auditors of the Company regarding compliance of the conditions of Corporate Governance as stipulated in the Listing Regulations, is enclosed.

MANAGEMENT DISCUSSION AND ANALYSIS:

Economic Scenario:

Anticipating a Global Reboot of the Economy

As per the International Monetary Fund (IMF), the global economy is estimated to grow by 5.5% in 2021 and 4.2% in 2022. The projection comes on the back of vaccine approvals, which is expected to spur the economy later this year. However, the effectiveness of policy support and access to medical interventions will determine the extent of recovery in different countries. This year's estimated growth follows a severe economic collapse in 2020 that has adversely impacted people globally. Based on the World Economic Outlook Update1, the global growth contraction for 2020, estimated at -3.5%, was 0.9 percentage point higher than the growth estimated in the previous forecast, driven by a stronger than expected reboot in the second half of 2020. We believe strong multilateral cooperation will form the basis of bringing the pandemic under control everywhere. Increasing funding for equitable access to COVID-19 vaccines for all countries, ensuring global distribution, and facilitating the therapeutics at affordable rates are essential measures to rein in COVID-19. Several countries, mainly the low-income developing economies, set foot into the crisis with a huge debt, which is expected to rise even further due to the pandemic. Therefore, there is a need for the global community to work collaboratively and ensure adequate access to international liquidity to help these countries.

Trends Impacting the Global Pharmaceutical Sector COVID-19 has impacted health and disease patterns and brought changes to several aspects of the pharmaceutical industry. Some of the emerging trends are highlighted below:

- 1. Demand for digital transformation
- 2. Advancements in technology and increasing R&D spends
- 3. Need for a new understanding of diseases
- 4. Affordable pricing and improved market access
- 5. Building a cohesive regulatory framework Demand for Digital Transformation

Since the onset of artificial intelligence (AI) and the data science revolution a few years ago, healthcare has consistently lagged in adoption, compared to other sectors, in leveraging these technologies. Noticeable trends that underscore the need for digital healthcare are evident, with COVID-19 further proving that health consultations can be

This Management Discussion and Analysis statement of the Annual Report has been included in adherence to the spirit enunciated in the code of corporate governance approved by the Securities and Exchange Board of India. Statement in the Management Discussion and Analysis describing Company's objectives, projections, estimates, expectation may be forward-looking statements within the meaning of applicable securities laws and regulations. Actual result could differ materially from those expressed or implied. Important factors that could make a difference to the Company's operation include economic conditions affecting demand/supply and price conditions in the Government regulations, tax laws and other status and other incidental factors. Further, the discussion following herein reflects the perceptions on major issues as on date and the opinion expressed here are subject to change without notice. The Company undertakes no obligations to publicly update or revise any of the opinions of

forward looking statements expressed in this report, consequent to new information future events, or otherwise.

Readers are hence cautioned not to place undue reliance on these statements and are advised to conduct their own investigation and analysis of the information contained or referred to this statement before taking any action with regard to specific objectives.

RISK MANAGEMENT:

A. Risk Management Committee

The Company has not constituted any risk management committee. However the Board as and when required reviews the Risk Management Policy.

B. Major risks affecting the existence of the company Business Risk

- Operating Environment
- Ownership Structure
- Competitive position
- Management, Systems and Strategy, governance structure

Financial Risk

- Asset Quality
- Liquidity
- Profitability
- Capital Adequacy

C. Steps taken to mitigate the risks:

Company has framed formal risk management policy. However Board of directors are constantly trying to avoid the risks by way of planning, developing strategies to remain in the market, reviewing government policies and procedures, and doing marketing activities to remain in the market.

CORPORATE SOCIAL RESPONSIBILITY:

This clause is not applicable.

DIRECTORS' RESPONSIBILITY STATEMENT:

Pursuant to Section 134(5) of the Companies Act, 2013, the Board of Directors, to the best of their knowledge and ability, state the following:

- That in the preparation of the annual financial statements for the year ended March 31, 2021, the applicable accounting standards have been followed along with proper explanation relating to material departures, if any;
- That such accounting policies as mentioned in Notes to the Financial Statements have been selected and applied consistently and judgement and estimates have been made that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at 31st March, 2021 and of the profit of the Company for the year ended on that date;

- That proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- > That the annual financial statements have been prepared on a going concern basis.
- That proper internal financial controls were in place and that the financial controls were adequate and were operating effectively.
- That systems to ensure compliance with the provisions of all applicable laws were in place and were adequate and operating effectively.

Key Managerial Personnel:

Mr. Alkesh M Gopani, Managing Director (Executive) and Mr. Alkesh R. Gosalia, Managing Director (Finance and Operations), were the KMP during the year and as at end of the year Mr. Alkesh R. Gosalia (Managing Director)_ Mr. Umang Gosalia, Whole-time Director, Mr. Keyur D Vora, Chief Financial Officer and CS Yash Vora, Company Secretary are the Key Managerial Personnel of the Company.

VIGIL MECHANISM/WHISTLE BLOWER POLICY:

Your Company is committed to highest standards of ethical, moral and legal business conduct. Accordingly, the Board of Directors have formulated a Whistle Blower Policy which is in compliance with the provisions of Section 177(10) of the Companies Act, 2013 and Regulation 22 of the SEBI (LODR), Regulations, 2015. It is framed for employees and Directors of the company to report to the management instances of unethical behaviour, actual or suspected fraud or violation of the company's code of conduct. This policy enables the employees or directors of Company to approach the Chairman of Audit Committee.

Further, the whistle blower policy is available at the website of our company at http://www.parmaxpharma.com/policies.php

THE CHANGE IN NATURE OF BUSINESS:

There is no material change in the business of the Company during the year under review.

PARTICULARS OF EMPLOYEES:

A statement containing the names and other particulars of employees in accordance with the provisions of section 197(12) of the Companies Act, 2013 read with rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is appended as "Annexure – D" to this report.

No employee has received remuneration in excess of the limits set out in rules 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 during FY 2020-21.

ACKNOWLEDGMENT:

The Directors wish to place on record their appreciation to the devoted services of the workers, staff and the officers who largely contributed to the efficient management of the Company in the difficult times. The Directors place on record their appreciation for the continued support of the shareholders of the Company. The Directors also take this opportunity to express their grateful appreciation for assistance and cooperation received from the bankers, vendors and stakeholders including financial institutions, Central and State Government authorities, other business associates, who have extended their valuable sustained support and encouragement during the year under review.

By and order of Board of Directors For, Parmax Pharma Limited

DATE: 14th August, 2021 PLACE: HADAMTALA

Dr. Umang Gosalia Managing Director DIN: 05153830

Annexure-A

FORM NO. AOC-2 (Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

1. Details of contracts or arrangements or transactions at arm's length basis:

SI	Names of related party and Nature of relationship	Nature of contracts/ arrangements/ transactions	Duration of contracts/arrangements/ transactions	Salient terms of the contracts/arrangements/ transactions	Justification for entering into such contracts or arrangements	Dates of approval by the Board	Amount paid as advances, if any	Date of special resolution u/s 188
	NA			N.A.	N.A.			N.A.

2. Details of contracts or arrangements or transactions not at arm's length basis:

SI	Names of related party and Nature of relationship	Nature of contracts/ arrangements/ transactions	Duration of contracts/ arrangements/ transactions	Salient terms of the contracts/arrangements/ transactions	Justification for entering into such contracts or arrangements	Dates of approval by the Board	Amount paid as advances, if any	Date of special resolution u/s 188
1	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.

By and order of Board Of Directors For, Parmax Pharma Limited

DATE: 14th August, 2021 Place: Hadamtala Dr. Umang Gosalia Managing Director DIN: 05153830

Annexure-B

Form No. MR-3 SECRETARIAL AUDIT REPORT FOR THE FINANCIAL YEAR ENDED 31st March, 2021

[Pursuant to section 204(1) of the Companies Act, 2013 and rule No.9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014]

Τo,

The Members, Parmax Pharma Limited Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Rajkot - 360311 Gujarat, India

I, Samsad Alam Khan, Company Secretaries, have conducted the secretarial audit of the compliance of applicable statutory (provisions and the adherence to good corporate practices by **PARMAX PHARMA LIMITED** [CIN: L24231GJ1994PLC023504] hereinafter called the Company). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of **PARMAX PHARMA LIMITED's** books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in my opinion, the Company has, during the audit period covering the financial year ended on 31st March, 2021 complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by **PARMAX PHARMA LIMITED** for the financial year ended on 31st March, 2021 according to the provisions of:

- I. The Companies Act, 2013 ('the Act') and the rules made there under;
- II. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
- III. The Depositories Act, 1996 and the Regulations and Byelaws framed there under;
- IV. Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings.
- V. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):
 - a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992 (upto 14th May, 2015) and Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (effective 15th May, 2015);

- c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 (Not Applicable to the Company during the Audit Period);
- d) The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014; (Not Applicable to the Company during the Audit Period);
- e) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008 (Not Applicable to the Company during the Audit period);
- f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client (Not Applicable as the Company is not registered as Registrar and Transfer Agents with SEBI);
- g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 (Not Applicable to the Company during the Audit Period) and;
- h) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998 (Not Applicable to the Company during the Audit Period).
- I. As informed to me the following other Laws specifically applicable to the Company as under:

A. INDUSTRIAL & LABOUR LAWS AND ENVIORNMENT RELATED:

- a) The Environment (Protection) Act, 1986
- b) The Factories Act, 1948
- c) The Minimum Wages Act, 1948
- d) The Payment of Wages Act, 1936
- e) Employee's State Insurance Act, 1948
- f) Employees' Provident Fund and Miscellaneous Provisions Act, 1952
- g) The Payment of Bonus Act, 1965
- h) The Payment of Gratuity Act, 1972
- i) The Contract Labour (Regulation and Abolition) Act, 1970
- j) The Maternity Benefit Act, 1961
- k) The Child Labour (Prohibition and Regulation) Act, 1986
- I) The Industrial Employment (Standing Orders) Act, 1946
- m) The Apprentices Act, 1961

I have also examined compliance with the applicable clauses of the following:

- a) Secretarial Standards with respect to General and Board Meetings Minutes issued by The Institute of Company Secretaries of India (effective from 1st July, 2015).
- b) The Listing Agreements entered into by the Company with BSE Limited.
- c) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. (effective from 1st December, 2015)

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above except to the extent as mentioned below.

- *i.* Company has not complied with the provisions of Section 74 of the Companies Act, 2013 regarding acceptance of deposits.
- *ii.* 100% Promoters' holding still not in D-mat form, 700 Equity Shares of Mr. Mahasukh Gopani is not in dematerialized form.

I further report that

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. Changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors, to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

All decisions of the board were unanimous and the same was captured and recorded as part of the minutes.

I further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

I further report that during the audit period there were no specific events / actions having a major bearing on the Company's affairs.

Place: Ahmedabad Date: 14.08.2021 Samsad Alam Khan Company Secretaries CP No: 13972 UDIN- A028719C000785585

Note: This Report is to be read with Our Letter of even date which is annexed as "Appendix A" and forms an integral part of this report.

'Appendix A'

To, The Members, Parmax Pharma Limited Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Rajkot - 360311 Gujarat, India

Our Secretarial Audit Report of even date is to be read along with this letter.

- 1. Maintenance of secretarial record is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.
- 2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
- 3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the company.
- 4. Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
- 5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.

The Secretarial Audit report is neither an assurance as to the future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company.

Place: Ahmedabad Date: 14.08.2021 Samsad Alam Khan Company Secretaries CP No: 13972

ANNEXURE - C

KEY FINANCIAL RATIOS

[Pursuant to Schedule V(B) to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015]

Description	2020-21	2019-20
Operating Profit Margin (%)	13.37	8.91
Net Profit Margin (%)	4.61	3.49
Debtors Turnover Ratio (in Months)	0.76	1.89
Inventory Turnover ratio (in Months)	1.81	1.56
Current Ratio	0.92	0.87
Debt Equity Ratio	1.01	1.04

Note- The Previous year figures have been regrouped/reclassified /recast, wherever considered necessary

By and order of Board Of Directors For, Parmax Pharma Limited

DATE: 29/06/2021

Dr. Umang Gosalia Managing Director DIN: 05153830

ANNEXURE - D TO DIRECTORS' REPORT

PARTICULARS OF EMPLOYEES:-

(Pursuant to rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules 2014.

- **1.** There increase in remuneration of each Director, Chief Financial Officer and Company Secretary during the financial year 2020-21 , ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the financial year 2020-21 .
- **2.** The percentage increase in remuneration of each director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the financial year;

Sr. No.	Name of Director/KMP	Remuneration for FY 2020-21 (in Rs)	% increase in remuneration in FY 2020-21	Ratio of remuneration of director to median remuneration of employees
1.	Mr. Alkesh M Gopani ^ Managing Director	Rs. 20,00,000/-	30 %	9.31x
2.	Mr. Alkesh R Gosalia \$ Managing Director	Rs. 39,00,000/-	30 %	15.13x
3.	Mr. Vipul M Gopani^ Non Executive Director	Nil	_	-
4.	Mr. Umang A Gosalia Managing Director	Rs. 19,80,000/-	32 %	7.68x
5.	Mrs. Asha S Daftary Independent Director	Nil	_	-
6.	Mr. Pramay A Chhatra Independent Director	Nil	-	-
7.	Mr. Keyur D Vora Chief Financial Officer	Rs.13,14,570/-	5.16%	5.10x
8.	CS Yash Vora Company Secretary	Rs. 5,01,930/-	18.60%	1.95x

^ Mr. Alkesh Gopani has resigned from the post of Managing Director and Director w.e.f. 8th February, 2021 % increase in remuneration is annualized is based on Remuneration .

^ Mr. Vipul M Gopani has resigned from the post of Director w.e.f. 2nd February, 2021

\$ Mr. Alkesh Gosalia ceased to be a director due to demise on 13.04.2021.

- 3. No sitting fees and commission paid to Independent Directors during the year under review
- 4. The number of employees on the rolls of the company as on March 31, 2021 is 82
- **5.** On an average, employees received an annual increment 14.29%. The individual increments varied from 5% to 20% based on individual performance. In order to ensure that remuneration reflects Company performance, the performance pay is also linked to organization performance, apart from an individual's performance.
- **6.** The remuneration stated above is in accordance with the remuneration policy of the company. During the Financial year No employee has received per annum remuneration exceeding Rs. 1.02 Crore or Rs. 8.50 Lacs per month.

CORPORATE GOVERNANCE REPORT

1. COMPANY'S PHILOSOPHY ON CODE OF GOVERNANCE:

The Company has always been committed to the principles of good corporate governance which inter alia includes protection of shareholders rights, enhancement of shareholder value, equitable treatment of all shareholders, stakeholders such as suppliers, customers and employees and to report financial information adequately and transparently. A continuous process of delegation of powers commensurate to accountability, coupled with trust, faith and transparency has been embedded in the day to day functioning. A system to effectively manage risks has been implemented. The Company has been disclosing detailed information on different issues concerned the Company's performance from time to time.

This report sets out the compliance status of the Company with the requirements of corporate governance, as set out in Pursuant to Regulation 34(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the financial year 2018-19.

Board of Directors

Name of the Director	Category	Total No. of Other Directorship (In Public Companies)	Details of Committees in other Companies	
			Chairman	Member
Alkesh R. Gosalia	Executive	Nil	Nil	Nil
Umang A. Gosalia	Executive	Nil	Nil	Nil
Asha S. Daftary	Independent	Nil	Nil	Nil
Pramay A. Chhatra	Independent	Nil	Nil	Nil
Ami R. Shah	Independent	Nil	Nil	Nil

A. Composition of Board of Directors as on 31st March, 2021 is as under:-

[^] Mr. Alkesh Gopani and Mr. Vipul Gopani were Directors during the Financial Year and they have resigned on 8th February and 2nd February, 2021 respectively.

B. Attendance of each director at the Board Meeting and Last Annual General Meeting:

During the financial year 2020-2021, the Board of Directors of your Company met 6 (Six) times on 12.06.2020, 31.07.2020, 15.09.2020, 12.11.2020, 16.01.2021 and 14.02.2021.

The details of directors and their attendance at the board meetings and Last Annual General Meeting of the Company are as under:-

Name of Directors	No. of Board Meeting attended	Attendance at last AGM held on 16 th October, 2020
Alkesh M. Gopani^	2	Yes
Alkesh R. Gosalia	6	Yes
Umang A. Gosalia	6	Yes
Vipul M. Gopani^	2	No
Asha S. Daftary	5	Yes
Pramay A. Chhatra	6	Yes
Ami R. Shah	4	No

[^] Mr. Alkesh Gopani and Mr. Vipul Gopani were Directors during the Financial Year and they have resigned on 8th February and 2nd February, 2021 respectively.

AUDIT COMMITTEE

The Audit Committee, comprising Three Directors, all are Non-Executive Directors and all of them have financial and accounting knowledge. The constitution of Audit Committee also meets with the requirements under Section 177 of the Companies Act, 2013 and as per Regulation 18 of SEBI (LODR) Reg, 2015. Members are regularly present at the meetings.

a. The Composition of an Audit Committee as on 31.03.2021 and details of committee meetings attended by members are as under:-

Mrs. Asha S. Daftary – Chairman Mr. Pramay A. Chhatra – Member Mr. Umang A. Gosalia – Member

There were four meetings held during the year dated 31/07/2020, 15/09/2020, 12/11/2020 and 12/02/2021.

Name of Members	Total Meetings held during the year	No. of meetings attended
Mrs. Asha S. Daftary	4	4
Mr. Pramay A. Chhatra	4	4
Mr. Umang A. Gosalia	4	4

- b. Keeping in view the provisions of section 177 of the Act, and the provisions of the SEBI (LODR) Regulations, 2015, the terms of reference of the Audit Committee include the following:-
- I. Oversight of the Company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
- II. Recommending the appointment, remuneration and terms of appointment of statutory auditors, including cost auditors of the Company;
- III. Approving payment to statutory auditors, including cost auditors, for any other services rendered by them;
- IV. Reviewing with management the quarterly and annual financial statements before submission to the board, focusing primarily on;
 - Matters required to be included in the Directors' Responsibility Statement to be included in the Board's Report in terms of clause (c) of sub-section 3 of Section 134 of the Companies Act, 2013;
 - > Changes, if any, in accounting policies and practices and reasons for the same;
 - Major accounting entries involving estimates based on the exercise of judgement by the management;
 - Compliance with listing and other legal requirements relating to financial statements;
 - Disclosure of any related party transactions; and
- V. Reviewing with the management, performance of statutory and internal auditors, external and Cost auditors, the adequacy of internal control systems, risk management systems.
- VI. Reviewing the adequacy of internal audit function, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit.
- VII. Discussion with internal auditors any significant findings and follow up there on.

- VIII. Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board.
- IX. Discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post audit discussion to ascertain any area of concern;
- X. Approval of appointment of CFO (i.e. the whole-time Finance Director or any other person heading the finance function or discharging that function) after assessing qualifications, experience and background, etc. of the candidate;
- XI. Reviewing the Company's financial and risk management policies.
- XII. To look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors.
- XIII. to review the functioning of the Vigil Mechanism/Whistle blower mechanism

NOMINATION AND REMUNERATION COMMITTEE

A. The composition of the Nomination and Remuneration Committee as on 31.03.2021 and the details of the meetings attended by the Directors are given below:

Mrs. Asha S Daftary – Chairman Mr. Pramay A Chhatra – Member Mr. Umang A. Gosalia – Member

The Meetings of Nomination and Remuneration Committee were held on and 16/01/2021 and 12/02/2021.

Name of Members	Total Meetings held during the	No. of meetings attended
	year	
Mrs. Asha S. Daftary	2	2
Mr. Pramay A. Chhatra	2	2
Mr. Umang A. Gosalia	2	2

- B. Keeping in view the provisions of section 178 of the Act and the provisions of the SEBI LODR Regulations 2015, the terms of reference of the Nomination and Remuneration Committee include the following.
- I. formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the board of directors a policy relating to, the remuneration of the directors, key managerial personnel and other employees;
- II. formulation of criteria for evaluation of performance of independent directors and the board of directors;
- III. devising a policy on diversity of board of directors;
- IV. identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the board of directors their appointment and removal;
- V. Whether to extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of independent directors.

During the period under review No sitting fee is payable to the Executive, Non Executive and Managing Director.

C. Details of shares of the Company held by Directors as on 31st March, 2021 are as under:

Name	No. of Shares held
Mr. Alkesh R Gosalia	254800
Mr. Umang A Gosalia	100000
Mrs. Asha S Daftary	Nil
Mr. Pramay A Chhatra	Nil
Ms. Ami Shah	Nil

STAKEHOLDER RELATIONSHIP COMMITTEE (erstwhile Shareholders'/Investors' grievance committee):-

A. The Composition of Stakeholder Relationship Committee as on 31.03.2021 and details of committee meetings attended by Director are as under:-

Mrs. Asha S Daftary – Chairman

Mr. Pramay A Chhatra – Member

Mr. Umang A. Gosalia – Member

The Meeting of Stakeholder Relationship Committee was held on 03/06/2020, 27/11/2020, 22/01/2021 and 12/02/2021 and all the members were present in the meeting.

B. Keeping in view the provisions of section 178 of the Act, and the provisions of the SEBI LODR Regulations 2015 the terms of reference of the Stakeholders Relationship Committee are as follows :-

- I. Oversee and review all matters connected with the transfer of the Company's securities;
- II. Approve issue of the Company's duplicate share / debenture certificates;
- III. Consider, resolve and monitor redressal of investors' / shareholders' / security holders' grievances related to transfer of securities, non-receipt of Annual Report, non-receipt of declared dividend etc.;
- IV. Oversee the performance of the Company's Registrars and Transfer Agents;
- V. Recommend methods to upgrade the standard of services to investors;
- VI. Monitor implementation and compliance with the Company's Code of Conduct for Prohibition of Insider Trading;
- VII. Carry out any other function as is referred by the Board from time to time and / or enforced by any statutory notification / amendment or modification as may be applicable.

C. Investor Grievance Redressal:-

Number of complaints received and resolved during the year as on 31st March, 2021 is as follows:-

Number of complaints as on 1 st April, 2020	1
Number of complaints received during the year ended on 31 st March, 2021	0
Number of complaints resolved up to 31st March, 2021	1
Number of complaints pending as on 31st March, 2021	0

Managing Director and CFO Certification

The Chairman/Managing Director and CFO have issued certificate pursuant to the provisions of under Regulation 17(8) of the (LODR) Reg, 2015 certifying that the financial statements do not contain any untrue statement and these statements represent a true and fair view of the Company's affairs. The said certificate is annexed and forms part of the Annual Report.

General Body Meetings

Details of last three Annual General Meetings are as under:

	Date	Time	Venue	No. of Special Resolutions
2017-18 2018-19 2019-20	22/09/2018 27/09/2019 16/10/2020	3.00 P.M. 1.00 P.M. 2.00P.M.	At Registered Office: Plot No. 20, Survey No. 52, Rajkot- Gondal National Highway No. 27, Rajkot – 360311, Gujarat, India	 Passed 1. Approval of Related Party transactions. 1. Approval of re-appointment of Mr. Alkesh Gopani as a Managing Director of the Company for a period of 2 years and revision in remuneration. 2. Approval of change in designation of Shri Alkesh Gosalia and Appointment as Managing Director for a period of 5 years and revision in remuneration. 3. Approval of change in designation of Mr. Umang
			Gujarat, India	Managing Director of 5 years and remuneration. 3. Approval of

One resolution was put through postal ballot during the financial year 2020-21 whose details are furnished below:

Special Resolution	No. of shares	No. of Votes polled	No. of Votes casted in favour	% of votes casted in favour	No. of Votes casted against	% of Votes casted against	Date of Declaration of Results
To issue, offer and allot equity shares on preferential basis to Promoters:	3741300	1310247	0	0	1310247	100	20.02.2021
To issue, offer and allot equity shares on preferential basis to Promoters (PAC):	3741300	1180997	0	0	1180997	100	20.02.2021
To issue, offer and allot equity shares on preferential basis to Non Promoters	3741300	2361797	0	0	2361797	100	20.02.2021

Due to non receipt of requisite majority from members of the Company the resolutions were not passed.

DISCLOSURES:

a) Disclosure on materially significant related party transactions:

Full disclosure of related party transactions as per accounting standard 18 issued by The Institute of Chartered Accountants of India is given under Note No. 22(H) of Notes Forming part of accounts for the year ended on 31st March, 2021.

The Board has approved a policy for related party transactions which has been uploaded on the Company's website. The web-link as required under Listing Regulations is as under: http://www.parmaxpharma.com/policies.php

- b) No. penalties or strictures have been imposed on the Company by Stock Exchange or SEBI or any statutory authority on any matter related to capital Markets.
- d) Independent Directors are familiarised with their roles, rights and responsibilities in the Company as well as with the nature of industry and business model of the Company. The details of the familiarisation programmes can be accessed on the web link: <u>http://www.parmaxpharma.com/policies.php</u>

Regulation 36(3) of SEBI (LODR) Regulations, 2015: Information relating to the Directors proposed to be appointed and those retiring by rotation and seeking re-appointment at this Meeting

Name	ne Umang A. Gosalia		Pramay Chhatra	
Date of Birth 23/04/1984		21/02/1949	19/08/1958	
DIN	05173830	07437167	07437291	
No. of Equity Shares held in the Company	1,00,000	NIL	NIL	
Relationship with other Directors/ Manager /KMP	None	None	None	
Education Qualification	M.Sc. and Doctorate in Organic (Chemistry)	Bachelor Degree in Arts.	Bachelor Degree in Science.	
Profile & Expertise in Specific functional Areas	Ph.D. (Doctorate in Organic (Chemistry) and having experience over a decade in chemistry & various types of organic reactions, and currently looking after the all production activities of the Company.	Having experience over a decade in general administration.	Having experience over a decade in general administration and science and technologies.	
List of other Directorship / Committee membership in other Companies as on 31 st March, 2021.	None	None	None	
Original date of appointment	Original date of 02.01.2016		12.02.2016	

MEANS OF COMMUNICATIONS

a) Financial Results:

The Company has regularly published its quarterly, half yearly & annual results in newspapers & submitted to stock exchanges in accordance with the Listing Agreement requirements. Company ordinarily published its quarterly reports in newspaper. Our Website address is http://www.parmaxpharma.com.

b) Website:

The Company's website <u>http://www.parmaxpharma.com</u> contains a separate dedicated section namely "Investors Relations" where shareholders information is available. The Annual Report of the Company is also available on the website of the Company.

The Management Discussion and Analysis Report forms part of the report.

GENERAL SHAREHOLDERS' INFORMATION:-

A. Annual General Meeting:-

Date: - 20th September, 2021 Venue:-Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot – 360 311 Gujarat, India

Time: - 2:00 P.M.

B. Financial Year: 2021-2022 (Tentative)

The financial year of the Company is 1st April to 31st March and financial results will be declared as per the following schedule.

Particulars	Tentative Schedule
Quarterly Unaudited Result	
Quarter Ending 30 th June, 2021	On 14 th August, 2021
Quarter Ending 30 th September, 2021	On or before 14 th November, 2021
Quarter Ending 31 st December, 2021	On or before 14 th February, 2022
Annual Audited Result	
Year ending 31 st March, 2022	Within 60 days from 31 March, 2022

C. Date of Book Closure:

The Share Transfer Book and Register of Members will remain closed from 14th September, 2021 to 20th September, 2021 (both days inclusive).

- D. Dividend: Nil
- E. Listing at following Stock Exchanges:

Name of the Stock Exchange	Stock Code
The BSE Limited (BSE)	540359
ISIN for Equity Shares held in Demat form with NSDL and CDSL	INE240T01014

G. Listing Fees:

The Company has paid the listing fees to Bombay stock exchanges.

H. Registrar & Share Transfer Agents:

Name & Address	:	PURVA SHAREGISTRY (INDIA) PVT. LTD.
		No-9, Shiv Shakti Industrial Estate, Ground Floor,
		J. R. Boricha Marg, Opp. Kasturba Hospital,
		Lower Parel, Mumbai - 400 011
		Tele No. : 022-2301 6761 / 2301 8261
		Fax No. : 022-2301 2517

I. Name of Company Secretary : CS Yash Vora

J. Income Tax PAN mandatory for Transfer of securities

As per Regulation 40(7) read with Schedule VII of the Listing Regulations, for registration of transfer of securities, the transferee(s) as well as transferor(s) shall furnish a copy of their PAN card to the listed entity for registration of transfer of securities.

Further, the amendment in Regulation 40 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, vide Gazette notification dated June 8, 2018, has mandated that transfer of securities would be carried out in dematerialized form only.

Kindly find enclosed letter with respect to the amendment of Reg. 40 of SEBI (LODR) Reg., 2015 alongwith first reminder letter for KYC updation of physical shareholders as mandated by SEBI vide its circular no. SEBI/HO/MIRSD/DOS3/CIR/P/2018/115 dated July 16, 2018 and Stock Exchange. Shareholders holding shares in physical mode are requested to send us the letter duly signed and filled providing us requisite attachments for KYC updation.

K. SHARE HOLDING PATTERN AS ON 31st MARCH, 2021:

Sr. No	Category	No. of Shares held	% of Share Holding
1	Promoters	1152450	30.80
2	Mutual Fund and UTI	0	0
3	Bank, Financial Institution, Insurance	0	0
	Companies (Central/State Government		
	Institution)		
4	Foreign Institutional Investors	0	0
5	Private Corporate Bodies	1610	0.04
6	Indian Public	2547525	68.09
7	HUF	30601	0.82
8	NRIs/OCBs	6386	0.18
9	GDR /ADR	0	0
10	Clearing Member	2728	0.07
	Grand Total :-	3741300	100.00

L. Outstanding GDR/ADRs/ Warrant or any convertible instrument, conversion and likely impact on equity:-

NIL

M. DISTRIBUTION OF SHAREHOLDING AS ON 31ST MARCH, 2021

SHAREHOLDING OF	NUMBER	% OF TOTAL	IN RS	% OF TOTAL
NOMINAL VALUE				
UPTO 5,000	433	46.56	1131540	3.02
5,001 - 10,000	112	12.04	998220	2.67
10,001 - 20,000	79	8.49	1302390	3.48
20,001 - 30,000	201	21.61	5140820	13.74
30,001 - 40,000	26	2.80	962730	2.57
40,001 - 50,000	39	4.19	1916130	5.12
50,001 - 1,00,000	23	2.47	1643200	4.39
1,00,001 & ABOVE	17	1.83	24317970	65.00
TOTAL =>	930	100	37413000	100

N. Registered Office Address for Correspondence

PARMAX PHARMA LIMITED

Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot – 360 311 Gujarat, IndiaWebsite: www.parmaxpharma.com Email Id: info@parmaxpharma.com Phone Number: - 02827 – 270534/270535

> By order of the Board of Directors For Parmax Pharma Limited

Date: 14th August, 2021 Place: Rajkot

Dr. Umang Gosalia Managing Director

DECLARATION OF COMPLIANCE WITH THE CODE OF CONDUCT

Pursuant to Regulation 26(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To, The Members, Parmax Pharma Limited Hadamtala, Dist. Rajkot

I, Dr. Umang Gosalia, Managing Director, of PARMAX PHARMA LIMITED hereby declare that all the board members and senior executives one level below the executive directors including all functional heads have affirmed for the financial year ended 31st March, 2021, compliance with the code of conduct of the Company laid down for them.

For Parmax Pharma Limited

Date: 14th August, 2021 Place: Rajkot

Dr. Umang Gosalia Managing Director DIN: 05153830

<u>Chief Executive Officer (CEO) / Chief Financial Officer (CFO) Certification under Regulation 17(8) of the (LODR)</u> <u>Reg, 2015</u>

To, The Board of Director Parmax Pharma Limited. Hadamtala, Rajkot.

We, Umang Alkesh Gosalia, Managing Director in terms of Companies Act, 2013 and Keyur D. Vora, Chief Financial Officer of the Company hereby certify to the Board that:

- **A.** We have reviewed financial statements and the cash flow statement of Parmax Pharma Limited for the year ended 31st March, 2021 and to the best of our knowledge and belief :
 - **1.** These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
 - **2.** These statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- **B.** There are, to the best of our knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or violative of the Company's code of conduct.
- **C.** We accept responsibility for establishing and maintaining internal controls for financial reporting and we have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting. We have not come across any reportable deficiencies in the design or operation of such internal controls.
- **D.** We have indicated to the auditors and the Audit committee:
 - **1.** That there are no significant changes in internal control over financial reporting during the year;
 - 2. That there are no significant changes in accounting policies during the year; and
 - **3.** That there are no instances of significant fraud of which we have become aware.

Date: 29.06.2021 Place: Rajkot

Dr. Umang Gosalia Managing Director Keyur D. Vora Chief Financial Officer

<u>CERTIFICATE REGARDING COMPLIANCE OF CONDITIONS OF CORPORATE</u> <u>GOVERNANCE</u>

To, The Members, **PARMAX PHARMA LIMITED**

We have examined the compliance of the conditions of Corporate Governance by **M/s. PARMAX PHARMA LIMITED** (the Company) for the year ended 31st March 2021, as stipulated in regulation 17 to 27 and 23 (4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") for the period from 1st April, 2020 to 31st March, 2021.

- 1. The Compliance of the conditions of Corporate Governance is the responsibility of the Company's Management. Our examination was limited to the procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of an opinion on the financial statements of the Company.
- 2. In our opinion and to the best of our information and according to our examination of the relevant records and the explanations made by the Directors and the Management, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in clause 49 of Listing Agreement and regulation 17 to 27 and clauses (b) to (i) of Regulation 46 (2) and para C,D and E of Schedule V of the Listing Regulations for the respective periods of applicability as specified under the paragraph 1 above, during the year ended on March 31, 2021.
- In our opinion and to the best of our information and according to the explanation given to us, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the SEBI (LODR) Regulations, 2015.
- 4. We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

Place: Ahmedabad Date: 14.08.2021 Samsad Alam Khan Practicing Company Secretary Membership No. A28719 Certificate of Practice No. 13972

Independent Auditor's Report

To the Members of Parmax Pharma Limited,

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the IND AS financial statements of **PARMAX PHARMA LIMITED** ("the Company"), which comprise the balance sheet as at **31**st **March 2021**, and the statement of Profit and Loss and statement of cash flows for the year then ended, and notes to the IND AS financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid IND AS financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2021, its profit/loss and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the IND AS Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the IND AS financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information other than the financial statements and auditors' report thereon

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report but does not include the IND AS financial statements and our auditor's report thereon.

Our opinion on the IND AS financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the IND AS financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the IND AS financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the IND AS financial statements of the current period. These matters were addressed in the context of our audit of the IND AS financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

<u>Responsibilities of Management and Those Charged with Governance for the Standalone Financial</u> <u>Statements</u>

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these IND AS financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards (IND AS) specified under section 133 of the Act read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the IND AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the IND AS financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the IND AS Financial Statements

Our objectives are to obtain reasonable assurance about whether the IND AS financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these IND AS financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also:

• Identify and assess the risks of material misstatement of the IND AS financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a

material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

• Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.

• Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

• Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the IND AS financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

• Evaluate the overall presentation, structure and content of the IND AS financial statements, including the disclosures, and whether the IND AS financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the IND AS financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

 As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the 'Annexure A', a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

- 2. As required by Section 143 (3) of the Act, we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit subject to above opinion.
 - *b)* In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c) The Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
 - d) In our opinion, the aforesaid IND AS financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 subject to above Opinion.
 - e) On the basis of the written representations received from the directors as on 31st March, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2021 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in 'Annexure B'.
 - g) With respect to the matter to be included in the Auditor's Report under section 197(16), In our opinion and according to the information and explanations given to us, the remuneration paid by the Company to its directors during the current year is in accordance with the provisions of section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under section 197(16) which are required to be commented upon by us.
 - h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

Place : Rajkot Date : 29.06.2021 UDIN:21159526AAAAAP8914 **For B A SHAH S R MEHTA & CO.** *Chartered Accountants* Firm Registration No.: 128796W

Malay Shah *Partner* Membership No. 159526

Annexure 'A'

The Annexure referred to in paragraph 1 of Our Report on "Other Legal and Regulatory Requirements".

We report that:

- i.
- a. The company has not maintained proper records showing full particulars, including quantitative details and situation of its fixed assets.
- b. The Fixed Assets have been physically verified by the management in a phased manner, designed to cover all the items over a period of three years, which in opinion of management, is reasonable having regard to the size of the company and nature of its business. Pursuant to the program, a portion of the fixed asset has been physically verified by the management during the year and no material discrepancies between the books records and the physical fixed assets have been noticed.
- c. The title deeds of immovable properties of Land and Building which are free hold as at the Balance Sheet Date are held in the name of the company.
- ii. As explained to us, inventories have been physically verified during the year by the management at reasonable intervals. No material discrepancy was noticed on physical verification of stocks by the management as compared to book records.
 - a. The discrepancies noticed on physical verification of the inventory as compared to books records which has been properly dealt with in the books of account were not material.
- According to the information and explanations given to us and on the basis of our examination of the books of account, the Company has not granted any loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or other parties listed in the register maintained under Section 189 of the Companies Act, 2013. Consequently, the provisions of clauses iii (a), (b) and (c)of the order are not applicable to the Company.
- In our opinion and according to the information and explanations given to us In respect of loans, investments, guarantees, and security, provisions of section 185 and 186 of the Companies Act, 2013 have been complied with.
- v. The Company has accepted deposits of Rs. 25 Lakh from Relative of Directors and hence the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the Companies (Acceptance of Deposit) Rules, 2015 with regard to the deposits accepted from the relative of Director is contravening. According to information and explanation provided to us, no order has been passed by Company Law Board or National Company Law Tribunal or Reserve Bank of India or any court or any other tribunal.
- vi. As per information & explanation given by the management, maintenance of cost records has not been specified by the Central Government under sub-section (1) of section 148 of the Companies Act, 2013.

vii.

- a. According to information and explanations given to us and on the basis of our examination of the books of account, and records, the Company has been generally regular in depositing undisputed statutory dues including Provident Fund, Employees State Insurance, Income-Tax, Sales tax, Service Tax, Duty of Customs, Duty of Excise, Value added Tax, Cess, GST and any other statutory dues with the appropriate authorities Except Staff Professional tax amounts payable Rs. 2,04,950 in respect of the above were in arrears as at 31st March 2021 for a period of more than six months from the date on when they become payable.
- b. According to the information and explanations given to us, there is no amount payable in respect of income tax, Goods and service tax, Service Tax, sales tax, customs duty, excise duty, value added tax and cess whichever applicable, which have not been deposited on account of any disputes.
- viii. In our opinion and according to the information and explanations given by the management, we are of the opinion that, the Company has not defaulted in repayment of dues to a financial institution, bank, Government or debenture holders, as applicable to the company.
- ix. Based on our audit procedures and according to the information given by the management, the company has not raised any money by way of initial public offer or further public offer (including debt instruments). However, Company has taken Mortgage GECL term loan of Rs. 73,48,000 during the year.
- x. According to the information and explanations given to us, we report that no fraud by the company or any fraud on the Company by its officers or employees has been noticed or reported during the year.
- xi. According to the information and explanations given to us, we report that managerial remuneration has been paid in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Companies Act.
- xii. The company is not a Nidhi Company. Therefore, clause (xii) of the order is not applicable to the company.
- xiii. According to the information and explanations given to us, all transactions with the related parties are in compliance with sections 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the IND AS Financial Statements etc. as required by the applicable accounting standards.
- xiv. Based upon the audit procedures performed and the information and explanations given by the management, The company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review. Accordingly, the

provisions of clause 3 (xiv) of the Order is not applicable to the Company and hence not commented upon.

- XV. Based upon the audit procedures performed and the information and explanations given by the management, The company has not entered into non-cash transactions with directors or persons connected with him Accordingly, the provisions of clause 3 (xv) of and provision of Section 192 of the Companies Act 2013 is not applicable to the Company and hence not commented upon.
- xvi. The company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934 and accordingly, the provisions of clause 3 (xvi) of the Order is not applicable to the Company and hence not commented upon.

Place : Rajkot Date : 29.06.2021 UDIN:21159526AAAAAP8914 For B A SHAH S R MEHTA & CO. Chartered Accountants Firm Registration No.: 128796W

Malay Shah *Partner* Membership No. 159526

Balance Sheet as at March 31, 2021

		Ато	unt In Rupees
Particulars	Note	As at	As at
	No.	31.3.2021	31.3.2020
I. Assets			
1. Non-current assets			
(a) Property, Plant and Equipment	1	108431440	96387453
(b) Capital work-in-progress		-	-
(c) Investment Property		-	
(d) Goodwill		-	
(e) Other Intangible assets		-	-
(f) Intangible assets under development		-	-
(g) Biological Assets other than bearer plants		-	-
(h) Financial Assets	_	-	-
(i) Investments	2	2006000	2006000
(ii) Trade receivables		-	-
(iii) Loans	3	1566698	1959560
(i) Deferred tax assets (net)	22		
(j) Other non-current assets	4	11884197	15845597
Total Non-Current Assets		123888335	116198610
2. Current assets		20524200	27220627
(a) Inventories	5	39531398	27238627
(b) Financial Assets	-	-	-
(i) Investments	-	-	-
(ii) Trade receivables	6	16542522	33046251
(iii) Cash and cash equivalents	7	25464478	17674876
(iv) Bank balances other than(iii) above	-	-	-
(v) Loans	8	21854512	16483967
(vi) Others (to be specified)	-	-	-
(c) Current Tax Assets (Net)	-	-	-
(d) Other current assets	-	-	-
Total Current Assets		103392910	94443722
Total Assets		227281245	210642331
II. Equity and Liabilities			
1. Equity			
(a) Equity Share capital	9	44511500	44511500
(b) Other Equity	10	13672664	6128446
Total Equity		58184164	50639945
2. LIABILITIES I. Non-current liabilities			
I. Non-current liabilities (a) Financial Liabilities			
(i) Borrowings	11	54332915	50335353
(ii) Trade payables		-	
(iii) Other financial liabilities		-	
(iii) Other than those specified in item (b),	-	-	
to be specified)			
(b) Provisions-		-	-
(c) Deferred tax liabilities (Net)		2308924	724952
(d) Other non-current liabilities-		-	-
Total of Non-Current Liabilities		56641839	51060305

Ami Shah

Director

Yash Vora

DIN: 08158605

Company Secretary

н.		Current	liabilities			
	(a)	Financial Liabilities				
		(ii)	Borrowings	-	-	-
		(iii)	Trade payables	12	99150700	96242617
		(iv)	Other financial liabilities	-	-	-
			(other than those specified in item (b),		
			to be specified)			
	(b)	Other o	current liabilities-	13	4928949	5354164
	(c)	Provisi	ons-	14	8375590	7345294
	(d)	Deferre	ed tax liabilities (Net)	-	-	-
_	Tota	al of Curi	rent Liabilities		112455238	108942075
_	Tota	al Equity	and Liabilities		227281245	210642331
	Αссοι	unting po	blicies	22		
	Othe	r Explana	itory notes	23, 24		

For B A Shah S R Mehta & Co. *Chartered Accountants* Firm Registration No.: 128796W

Malay Shah Partner Membership No. 159526 UDIN: 21159526AAAAAP8914

Date : 29.06.2021 Place : Rajkot For Parmax Pharma Limited

Dr. Umang Gosalia Managing Director DIN: 05153830

Keyur Vora CFO

Date : 29.06.2021 Place : Rajkot

Statement of Profit and Loss Account

Amount In Rupees

Sr. No.	Particulars	Note	Year Ended	Year Ended
			31.03.2021	31.03.2020
			(Audited)	(Audited)
۱.	Revenue from operations	15	2620.45	2093.41
11.	Other income	16	8.89	9.78
III.	Total Income (I+II)		2629.34	2103.19
	Expenses			
	(a) Cost of materials consumed	17	1341.18	1121.34
	(b) Purchase of stock-in-trade		_	-
IV.	(c) Changes in inventories of finished goods, work-in-progress and stock-in- trade	18	2.31	5.25
	(d) Employee benefits expense	19	35388780	29139115
	(e) Finance Costs	20	3542515	1273691
	(f) Depreciation and amortization expense	1	19415616	10071526
	(g) Other expenses	21	58153846	49868688
	Total expenses (IV)		250849653	203012501
V	Profit/(Loss) from operations before exceptional items and tax (I-IV)		12084397	7306367
VI	Exceptional Items		<u>.</u>	_
VII	Profit/ (Loss) before tax (V-VI)		12084397	7306367
	Tax expense:			
VIII	(1) Current tax		2820000	1500000
	(2) Deferred tax		1583972	1519577
	(3)Current tax expenses relating to prior year		136207	-
IX	Profit / (Loss) for the period from continuing operations (VII-VIII)		7544218	4286790
х	Profit/(loss) from discontinued operations		-	-
XI	Tax expense of discontinued operations		-	-
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)		-	_
XIII	Profit (Loss) for the period (IX+XII)		7544218	4286790
XIV	Other Comprehensive Income A. (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss B. (i) Items that will be reclassified to profit or loss (ii) income tax relating to items that will be reclassified to profit or loss		-	-
xv	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)		7544218	4286790
XVI	Paid-up equity share capital (Face Value Rs 10)		3741300	3741300
	Earnings per share (for continuing operation)			
XVII	(of Rs. 10/- each):			

	(a) Basic			2.02	1.15
	(b) Diluted			-	-
	Earnings per share (for discontinuing operation)				
	(of Rs. 10/- each):				
XVII	(a) Basic		-	-	
	(b) Diluted		-	-	
	Earnings per share (for continuing operation & discontinuing operation)				
	(of Rs. 10/- each):				
XVII	(a) Basic			2.02	1.15
	(b) Diluted		-		-
	Accounting policies	22			
	Other Explanatory notes	23,24			

For B A Shah S R Mehta & Co. Chartered Accountants	For Parmax Pharma Limited	
Firm Registration No.: 128796W	Dr. Umang Gosalia Managing Director DIN: 05153830	Ami Shah Director DIN: 08158605
Malay Shah Partner		
Membership No. 159526 UDIN: 21159526AAAAAP8914	Keyur Vora CFO	Yash Vora Company Secretary
Date : 29.06.2021 Place : Rajkot	Date : 29.06.2021 Place : Rajkot	

CASH FLOW STATEMENT FOR THE YEAR ENDED 31st MARCH , 2021

_	PARTICULARS		Period Ended on	Unt In Rupees Period Ended on	
	PARTICULARS		31/03/2021	31/03/2020	
<u>A)</u>	CASH FLOW FROM OPERATING ACTIVITIES				
	Net Profit After Extraordinary Item but Before Taxation:				
	Adjustments for:		12,084,397	7,306,367	
	Depreciation		19,415,616	10,071,526	
	Provision for Current Tax		2,820,000	1,500,000	
	Current tax expenses relating to prior year		136,207		
	Operating profit before Working Capital changes		28,543,806	15,877,893	
	Adjustments for changes in Working Capital:		20,343,000	13,077,033	
	(Increase) / Decrease in Inventories		(12,292,771)	12,457,897	
	(Increase) / Decrease in Trade & Other Receivables		16,503,729	(21,586,036	
	(Increase) / Decrease in Short termLoans and Advances		(5,370,545)	7,021,632	
	Increase / (Decrease) in Current Liabilities		2,482,867	6,497,340	
	Increase / (Decrease) in Provisions		1,030,295	4,290,752	
	(Increase) / Decrease in Non Current Assets		3,961,400	3,961,400	
	(Increase) / Decrease in Long term Loans & Advances		392,862	(272,747	
	Cash generated from Operations		6,707,838	12,370,238	
	Net Cash from Operating activities	(A)	35,251,644	28,248,133	
(<u>B)</u>	CASH FLOW FROM INVESTING ACTIVITIES				
	Purchase of Fixed Assets		(31,459,603)	(23,992,643	
	Net Cash from / (Used in) Investing activities	(B)	(31,459,603)	(23,992,643	
(C)	CASH FLOW FROM FINANCING ACTIVITIES				
	Increase / (Decrease) in other Long Term Borrowings		3,997,562	(2,254,690	
	(Increase)/ Decrease in Non Current Investment				
	Net Cash (Used in) Financing activities	(C)	3,997,562	(2,254,690	
	Net Increase in Cash & Cash Equivalents		7,789,602	2,000,79	
	(A + B + C) Cash & Cash Equivalents at the beginning of the year		17,674,877	15,674,082	
	Cash & Cash Equivalents at the end of the year		25,464,479	17,674,877	
For	3 A Shah S R Mehta & Co.	For Parmax Pharma Limited			
	rtered Accountants				
	Registration No.: 128796W	Dr. Umang Gosalia	Ami Shah		
		Managing Director	Director		
	Ch - h	DIN: 05153830	DIN: 08158605		
	ay Shah				
Part Men	<i>ner</i> nbership No. 159526	Keyur Vora	Yash Vora		
	N: 21159526AAAAAP8914	CFO	Company Secre	etary	
Date		Date : 29.06.2021			
Plac	e : Rajkot	Place : Rajkot			

NOTES FORMING PART OF BALANCE SHEET AS AT 31.03.2021

		As at March 31, 2021 Rs	As at March 31, 2020 Rs
2. NON-CURRENT INVESTMENTS			
Unquoted Investment			
National Saving Certificate		6,000	6,000
HDFC Fix Deposit - Earmarked Balances with banks (Balances held as margin money against guarantees - Bank Guarantee with HDFC Bank)		2,000,000	2,000,000
	Total	2,006,000	2,006,000
3. LONG-TERM LOANS AND ADVANCES			
(Unsecured and considered good)			
Security deposits		1,566,698	1,959,560
	Total	1,566,698	1,959,560
4. OTHER NON CURRENT ASSETS			
Miscellaneous Expenses		11,884,197	15,845,597
	Total	11,884,197	15,845,597
5. INVENTORIES Raw material		24,024,209	16,942,268
Stores & Consumables Work in Process Finished goods		389,000 15,118,189 -	620,000 9,676,359 -
	Total	39,531,398	27,238,627
6. TRADE RECEIVABLES (Unsecured and considered good) Exceeding six months		1 220 425	27.274
Unsecured, Considered Good Less than six months		1,338,425	37,274
Unsecured, Considered Good		15,204,097	33,008,977
	Total	16,542,522	33,046,251
7. CASH AND CASH EQUIVALENTS Cash on hand Bank Balance		251,391	388,906
- Balance with banks		25,213,088	17,285,971
	Total	25,464,479	17,674,876
8. SHORT TERM LOANS AND ADVANCES			
(Unsecured and considered good)			
Advance to Suppliers Advance Recoverable in Cash or in kind or for Value to be received		1,446,276 20,408,236	54,134 16,429,833
	Total	21,854,512	16,483,967

9. SHARE CAPITAL

AUTHORISIED

6000000 Equity shares of RS.10/- each	60,000,000	60,000,000
	60,000,000	60,000,000
Issued, Subscribed and Fully paid-up		
5100800 Equity shares of Rs.10/- each, fully paid up	51,008,000	51,008,000
Less:		
Calls in Arrears / unpaid Allotment Money (13,59,500 Equity Shares)	13,595,000	13,595,000
	37,413,000	37,413,000
Add: Share Forfeiture (Partly Paid up 13,59,500 Equity Shares forfeited)	7098500	7,098,500
	44,511,500	44,511,500

	31.03.2	31.03.2021		.2020
Particulars	No. of Shares	Amount (in Rs.)	No. of Shares	Amount (in Rs.)
Reconciliation of Shares				
Fully Paid up Shares Outstanding At the Beginning of the Year	1	3,741,300	37,413,000	3,741,300
Partly Paid Shares Outstanding At the Beginning of the Year	-	-		-
Add:				-
Shares Issued During the Year	-	-	-	-
Partly Paid up Shares converted into Fully Paid Up	-	-	-	-
Calls in Arrears received during the year	-	-	-	-
Less:				
Shares Bought back during the year	-	-	-	-
Fully Paid up Shares Outstanding At the End of the Year	3741300	37413000	3741300	37413000
Partly Paid Shares Outstanding At the End of the Year	-	-	-	-
Share Forfeited by the Company	1,359,500	7,098,500	1,359,500	7,098,500

Equity shares

The Company has issued only one class of shares referred to as equity shares having nominal value of Rs.10/-. Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the company, the holders of equity shares will be entitled to receive any remaining assets of the company, after distribution of all preferential amounts in proportion to their shareholding. The company and the promoters of the Company both shall have first right of refusal before transfer of Equity Shares by either of them.

Shareholders holding more than 5% shares based on legal ownership in the subscribed share capital of the Company is set out below :

		As at March 31, 2021		As at March 31, 2020	
Name of the shareholder	No. of Shares	% held	No. of Shares	% held	
Mahasukhlal Chimanbhai Gopani	700	0.02%	748960	20.02%	
Pravina Mahashukh Gopani	762340	20.38%	14080	0.38%	
Alkesh M Gopani	289210	7.73%	289210	7.73%	
Alkesh R Gosalia	254800	6.81%	254800	6.81%	
Pradip R Gosalia	250000	6.68%	250000	6.68%	
Shah Jyotsana Ramniklal	250000	6.68%	250000	6.68%	
Others	1934250	51.70%	1934250	51.70%	
Total	3741300	100%	3741300	100%	

10. RESERVES AND SURPLUS

Surplus/(Deficit) in the Statement of Profit and Loss

	Total	13,672,664	6,128,446
Less : Transferred		-	-
Closing Balance		13,672,664	6,128,446
Add : Profit/(loss) for the year		7,544,218	4,286,790
Opening balance		6,128,446	1,841,656

11. LONG-TERM BORROWINGS

Secured			
HDFC Bank Loan - Term Loan from HDFC Bank Loan is payable by way of monthly installment of 513220/- each. The Loans is secured against all the Immovable property situated on the land admn. Sq. Mtr. 15903.91 ie. 19021.54 Sq. Yards of Plot No. 20, Survey No. 52/P Hadamtala Tal. Kotda Sangani, Dist. Rajkot		34,462,490	36,504,902
HDFC Bank Loan A/c. - Loan was sanctioned during FY 2020-21 under the scheme of LAP MORTGAGE GECL From HDFC Bank Ltd. The loan is repayable by way of monthly installment of Rs. 2, 31,108/- each along with interest.		7,348,000	-
HDFC Bank Ltd - Motor Car Loan A/C		857,612	1,176,371
- HDFC Bank Ltd Vehicle Loan (against Hypo. KIA Seltos) is repayable in Monthly installment of Rs. 41490 each along with interest. The loan is secured by hypothecation of KIA Seltos Car of the company.	C L		
	Sub - Total	42,668,101	37,681,273
Unsecured			
From Directors		1,200,000	2,257,350
From Directors Relatives		2,500,000	2,500,000
From Earstwhile Director		9,995,000	10,100,000
Loans from Corporate Bodies where Common Directors are Interested - Loan From Directors - Loan from Umang Gosalia Carries 15% Interest P.a.			2,500,000
	Sub- Total	16,195,000	14,857,350
Total Long Term Borrowings (Secured & Unsecured)		58,863,101	52,538,623
Less: Current maturities of long-term borrowings at the year end		4530187	2203270
(Disclosed Under the Head "Other Current Liabilities"(Note No. 13)			_

Parmax Pharma Limited	27	th Annual R	eport
	Total	54,332,915	50,335,353
The Above Amount Includes			
Secured Borrowings		42,668,101	37,681,273
Unsecured Borrowings		16,195,000	14,857,350
	Total	58,863,101	52,538,623
12. TRADE PAYABLES			
Trade payables			
For Goods & Services		65,110,923	64,938,157
Up To One Year		55,701,499	55,383,450
More than One Year		9,409,424	9,554,707
For Expenses		6,525,502	4,939,942
For Capital Expenditure		27,514,275	26,364,518
	Total	99,150,700	96,242,617
13. OTHER CURRENT LIABILITIES			
Other Current Liability		398,762	153,146
Advance from Customers		-	2,997,749
Current maturities of Long Term Debts		4,530,187	2,203,270
	Total	4,928,949	5,354,164
14. SHORT TERM PROVISIONS			
Provision for Taxes		2820000	1,500,000
Duties and Taxes		220,790	1,437,605
Provision for Expenses		5,334,800	4,407,690
	Total	8,375,590	7,345,295

NOTES FORMING PART OF PROFIT & LOSS ACCOUNT

FOR THE YEAR ENDED 31.03.2021

	For The year ended March 31, 2021 (Rs.)	For The year ended M arch 31, 2020 (Rs.)
15. REVENUE FROM OPERATIONS Local	248,079,903	193,593,479
Labour Job Work	13,784,539	15,747,602
Freight Outward Exp. (Sales)	181,000	0
 Total	262,045,442	209,341,081
16. OTHER INCOME		
Bank Interest Income	561,953	694,664
Credit card incentives A/c.	1,517	4,512
Credit Written Back A/c	0	0
Foreign Exchange Rate Diffrence (Gain/Loss) A/c.	0	(7,992)
Interest on Income Tax Refund A/c.	55,784	0
Interest Income on PGVCL Security Deposit	53,600	70,848
Tower Rent Income	215,754	215,754
Total	888,608	977,787
17. COST OF MATERIALS CONSUMED		
Opening stock of Raw Material	16,942,268	14,677,503
Opening of Stock in process	9,676,359	23,874,221
	26,618,627	38,551,724
Add: Raw Material Purchase	144,947,399	99,274,852
Add: Custom Duty on Import A/c.	310,514	0
Add: Opening of Stock in process		
Add: Freight Exp.	1,289,952	912,363
Add :Import Clearing & Forwarding Exp.	45,897	5,698
Add :Import Freight & Other Exp.	47,905	8,669
Add: Rickshaw Fare Exp.	0	0
-	173,260,294	138,753,307
Less: Closing stock of Raw Material	24,024,209	16,942,268
Less: Closing Stock S.I.P	15,118,189	9,676,359
	39,142,398	26,618,627
Total	134,117,896	112,134,680

18. (INCREASE)/DECREASE IN INVENTORIES

Closing inventories			
Finished goods		0	0
Stores		389,000	620,000
	Sub-Total	389,000	620,000
Opening inventories			
Finished goods		0	349,800
Stores		620,000	795,000
	Sub-Total	620,000	1,144,800
	Total	231,000	524,800
19. EMPLOYEE BENEFITS EXPENSE			
Salary & Wages		35,130,280	28,773,115
Other Benefit		258,500	366,000
			20.420.445
	Total	35,388,780	29,139,115
20. FINANCE COSTS		105 700	102.015
Bank Charges & Commission		105,796	102,015
Motor Car Loan Interest		95,109	41,574
Interest Exp		3,341,611	1,130,103
	Total	3,542,515	1,273,691
21. OTHER EXPENSES			
Manufacturing Expenses			
Consumable Exp.		3,229,212	2,921,315
Canteen Exps.		1,891,900	861,690
ETP Maintenance Exp.		1,966,430	2,581,437
Electricity Exps.		11,388,716	9,957,631
Fuel Expenses		9,158,561	11,760,146
Hydrogenation Job work Charges		4,385,009	1,258,325
Boiler Repairs & Replacement Exps.		58,300	200,460
Plant Repairs & Maintenance Exps.		4,598,407	2,796,663
Safety Equipment Exp.		232,408	166,088
Local Transportation & Rickshaw Fare Exp.		509,810	587,415
Comple Testing Changes		1,343,555	1,009,975
Sample Testing Charges			
Sample Testing Charges Sundry Factory Exps.		1,339,642	344,699

Administration & Selling Exps.

Advertisement Expense 100,868 229,580 95,000 Audit Fees 150,000 Air Conditioner Repairs and maintenance 79,950 106,850 Bad Debts A/c. 670,697 0 Books & Periodicals Exp. 3,300 1,500 Building Repairs and maintenance 1,394,335 521,573 **Computer Repairs & Maintenance Exp** 230,287 78,247 Charity & Donation Exp. 337,602 303,901 0 Co. Professional Tax Exp. 7,200 0 33,000 Corporate Social Responsibility Exp. Credit card charges A/c. 12,997 34,718 **Discount & Remission** (876) 804 Electric Maintenance Exps. 339,808 176,249 Freight outward Exp 571,452 172,200 Food & Beverages Exps. 104,371 210,277 Foreign Travelling Expenses (Others) 0 165,773 0 Travelling Expense (Others) 164,690 Director Travelling Expense (Domestic - Foreign) 805,400 86,137 Furniture & Fixtures Repairing Exps. 44,560 62,940 Garden Exps. 43,300 150,300 **GST Tax Expenses** 268,150 141,569 38,410 0 GST Interest A/c. Hotel Accommodation Exp. 86,701 182,962 Insurance Exp 582,162 447,427 Income Tax Interest A/c. 130,482 0 Land Revenue Exp. 21,770 0 Legal Fees Exp. 0 65,600 Professional Fees Exp. 2,616,889 630,393 License Application/ Renewal Fees A/c 94,697 372,842 Laboratory Repairing Exps. 487,078 485,882 Loading & Forwarding 8,700 200 Membership & Subscription Exps. 67,954 65,771 Motor Car Fuel Exp. 585,679 709,519 Motor Car Insu. Premium A/c. 135,111 99,424 Motor Car Repairing Exps. 421,049 530,136 Manpower Service Charge 51,480 50,812 Postage & Courier Exp 158,256 160,713 Packaging and Forwarding Expenses 1,104,852 793,850 Pre-Operative Exp. Written Off 3,961,400 3,961,400

	18,051,896	15,422,844
Round Off	0	2
Weigh Scale Exp.	34,105	49,850
Vehicle Fuel Expenses	0	100
Sales Promotion Exp	0	772,017
Sundry Balance Written off a/c	0	691,319
Sundry Repairs Exp.	29,382	8,000
Sundry Expenses	304,208	644,570
Stock Exchange Fees	300,000	300,000
Provident Fund Expenses	14,550	13,525
Staff Welfare Expense	1,790	40,875
Staff Travelling Allowance & Conveyance Exp.	225,780	141,660
Staff Cloth Exps.	41,148	0
Staff Medical Exps.	352,907	83,143
Security Expense	241,513	264,000
Statutory Analytical Charges	22,198	0
TDS Interest A/c.	2,108	2,414
Telephone Repairing Exp.	3,510	9,610
Telephone Exp	113,287	102,358
Tea-Coffee Exp	523,888	463,755
Stationary Printing & Xerox Exp	361,880	237,367
Professional Training, Coaching & Development Exp.	40,000	0
Prior Period Expenses	0	29,614

22. SIGNIFICANT ACCOUNTING POLICIES :

 IND AS 1 PRESENTATION OF FINANCIAL STATEMENTS : These financial statements have been prepared under historical cost convention from books of accounts maintained on an accrual basis (unless otherwise stated hereinafter) in conformity with accounting principles generally accepted in India and comply with the Accounting Standards issued by the Institute of Chartered Accountants of India and referred to Section 133 read with Rule 7 of the Companies (Accounts) rules, 2014 except as required by IND AS 19 -Employee benefits. The accounting policies applied by the company are consistent with those used in previous year.

The preparation of financial statements in conformity with GAAP requires that the management of the company makes estimates and assumptions that affect the reported amounts of income and expenses of the period, the reported balances of assets and liabilities and the disclosure relating to contingent liabilities as of the date of the financial statements.

All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle as arrived at by management, and other criteria set out in the revised Schedule III Division II to the Companies Act, 2013, based on the nature of products and the time between the acquisition of assets for processing and their realization in cash and cash equivalents. The comparative figures in the Balance Sheet as at March 31, 2021 and March 31, 2020 and Statement of profit and loss and Cash Flow Statement for the year ended March 31, 2021 have been restated accordingly. Accounting Policies have

been consistently applied except where newly issued accounting standards is initially adopted or revision to existing standards required a change in the accounting policy thereto in use. Management evaluates all recently issued or revised accounting standards on and on-going basis.

2. IND AS 16 PROPERTY, PLANT and EQUIPMENT : Fixed Assets are stated at historical cost less accumulated depreciation and impairment losses, such cost being exclusive of excise duty/GST. The cost of an asset comprises its purchase price and directly attributable cost of bringing the assets to working condition for its intended use. Expenditure for additions and improvements are capitalized as and when incurred.

DEPRECIATION : Depreciation for the year on all assets is provided for on written down value method. (i) On carrying amount of fixed Asset brought forward from earlier year, at the rates derived from estimates of useful lives made by management as mentioned in following table, (ii) on Fixed assets added during the year, at the rates derived from useful lives stated in schedule II to Companies Act, 2013.

Sr. No.	Major Head	Asset Included	Useful life
1	Building	Building	30 years
2	Plant and Machinery	All Plant and Machinery	15 years
3	Furniture and Fixures	All Furniture and Fixures	10 years
4	Office Equipment	All office Equipment	5 years
5	Vehicles	All Motor car	10 years
6	Computer and data processing units	All Computer related Items	6 years

3. FINANCIAL LIABILITIES :

Initial Recognition and Measurement: Financial Liabilities are initially recognized at fair value plus any transaction costs, (if any) which are attributable to acquisition of the financial liabilities.

4. CURRENT/ NON CURRENT CLASSIFICATION :

An asset is classified as current if:

- (a) It is expected to be realized or sold or consumed in the Company's normal operating cycle;
- (b) It is held primarily for the purpose of trading;
- (c) It is expected to be realized within twelve months after the reporting period; or
- (d) It is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability classified as current if :

- (a) It is expected to be settled in normal operating cycle;
- (b) It is held primarily for the purpose of trading
- (c) It is expected to be settled within twelve months after the reporting period
- (d) it has no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.
- 5. SHARE CAPITAL: Ordinary Shares are classified as equity. Incremental costs directly attributable to the issue of new Ordinary shares or share options are recognized as a deduction from equity, net of any tax effects.
- INVESTMENTS : The Company hold no investment. Long term Investments are stated at cost. Provision for diminution in the value if long term investment is made only when such decline is not temporary

- 7. IND AS 18 REVENUE : Revenue is recognized only when it is probable that the economic benefits associated with the transaction will flow to the entity. Sales are exclusively of VAT, Excise Duty and Service Tax and GST.
- 8. PURCHASE : Purchase of Raw Material where Cenvat credit and VAT credit and GST Credit is available are exclusive of Excise duty and VAT, GST
- 9. IND AS 2 INVENTORIES : The cost of inventories shall comprise all costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition. Inventories should have been Valued as below :

Raw Material & Stores : Lower of Cost or Net Realizable Value Semi Finished Goods/WIP Stock : At RM Cost + Conversion Cost Finished Goods : Lower of Cost or Net Realisable Value

Company has maintained WIP stock records at Raw Material Cost however Conversion Cost as per Ind AS-2 Inventories has not been maintained/made available by company to verify and quantify VALUE OF W I P Stocks and its impact on true and correctness of Financial Statements prepared in accordance with Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India

10. IND AS 12 INCOME TAX: Current year tax is provided based on the taxable income computed in accordance with the Income Tax Act 1961 Deferred Tax is recognized, subject to consideration of prudence, on timing differences, representing the difference between the taxable income/loss and accounting income/loss that originated in one period and are capable of reversal in one or more subsequent periods. Deferred Tax assets and liabilities are measured using tax rules and tax laws that have been enacted or substantively enacted by the Balance Sheet date. Deferred tax assets Viz. unabsorbed depreciation and carry forward losses are recognised if there is virtual certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized.

In accordance with IND AS 12, "Income Tax", issued by The Institute of Chartered Accountants of India, the company has recognised deferred tax liabilities for the current year. The company has started generating cash profits and based on the future projections, the management is certain that the company shall be able to avail setoff of the carried forward losses against taxable profits.

Deferred Tax Liability as on 01.04.2020	724,952
Add:	
Provision for Deferred tax Asset during the financial year on account of depreciation	1,583,972
Deferred Tax Liability as on 31.03.2021	2,308,924

11. IND AS 19 EMPLOYMENT BENEFITS : Employees Benefits are accounted on cash basis. Though Accounting Standard IND AS 19 issued by the Institute of Chartered Accountants of India is mandatory, the firm has not made Provision for Leave Encashment Benefit and payment of gratuity on retirement of employee as the quantum of liability is not ascertainable due to the availability of leave encashment benefit and availment of leave any time during the service period. There were no share based payments made to any of the employees.

12. IND AS 24 RELATED PARTY DISCLOSURES:

 Key Management Personnel Mr. Alkesh R. Gosalia*
 Mr. Umang Alkesh Gosalia
 Ms. Asha S Daftary
 Mr. Pramay Chhatra
 Ms. Ami Rajeshbhai Shah
 Mr. Yash Vora
 Mr. Keyur Vora

*Deceased on 13.04.2021

(II) Enterprises owned or significantly influenced by Key Management personnel or their relatives M/s Malwin Pharma Pvt Ltd - Mr. Alkesh Gosalia was common Director

Sr. No.	Name of Person / Entity	Relation	Nature of Transaction	Amount Involved
1	Alkesh R. Gosalia [^]	Managing Director	Director Salary	3900000
2	Alkesh M. Gopani *	Managing Director	Director Salary	2000000
3	Umang A. Gosalia	Executive Director	Director Salary	1980000
4	Umang A. Gosalia	Executive Director	Accrual / payment of Interest	75484
5	Umang A. Gosalia	Executive Director	Loan Repaid	1000000
6	Pradeep R. Gosalia	Brother of Director	Salary	1200000
7	Nimit P. Gosalia	Nephew of Director	Salary	540000
8.	Malwin Pharma Pvt Ltd	Alkesh Gosalia was Common Director	Acceptance of loan	2500000

* Mr. Alkesh Gopani has resigned from the post of Managing Director and Director w.e.f. 8th February, 2021

^ Mr. Alkesh Gosalia ceased to be a director due to demise on 13.04.2021.

13. IND AS 108 OPERATING SEGMENT : The company has only one principal place of business and operates in only one type of business hence segment reporting is not made.

14. IND AS 20 ACCOUNTING FOR GOVERNMENT GRANTS AND DISCLOSURE OF GOVERNMENT ASSISTANCE : The Govt. Grants subsidies or exort incentives received by the company are properly accounted.

- 14. IND AS 23 BORROWING COST : Borrowing costs that are attributable to acquisition or construction of qualified as part of the cost such assets. A Qualifies asset is one that takes substantial period of time to get ready for intended use. All other borrowing costs are charged to revenue.
- 15. IND AS 17 LEASES : The company has not entered in to any lease transaction during the financial year, hence the clause is not applicable.
- 16. IND AS 36 IMPAIRMENT OF ASSETS : The carrying values of assets/cash generating units at each Balance Sheet date are reviewed for impairment. If any indication of impairment exists, the recoverable amount of such assets is estimated and impairment is recognised, if the carrying amount of these assets exceeds their recoverable amount. The recoverable amount is the greater of the net selling price and their value in use.

Value in use is arrived at by discounting the future cash flows to their present value based on an appropriate discount factor. When there is indication that an impairment loss recognised for an asset in earlier accounting periods no longer exists or may have decreased such reversal of impairment loss is recognized in the Statement of Profit and Loss, except in case of revalued assets.

In opinion of management, there are no indication of impairment of assets as on 31.03.2021 so no effect of impairment is required to be given in books of accounts.

- 17. IND AS 37 PROVISIONS CONTINGENT LIABILITIES AND CONTINGENT ASSETS : Provision is recognised when the Company has a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions (excluding retirement benefits) are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the Balance Sheet date. These are reviewed at each Balance Sheet date and adjusted to reflect the current best estimates.
- 18. IND AS 8 ACCOUNTING POLICIES, CHANGES IN ACCOUNTING ESTIMATES AND ERRORS : The preparation of financial statements requires, estimates and assumptions to be made that affect the application of accounting policies and the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed at each Balance Sheet date. Revisions in the estimates are recognized in the periods in which the results are known/materialize.

19. IND AS 33 EARNINGS PER SHARE (EPS):

Particulars	As at March 31,2021	As at March 31,2020
Basic/ weighted average number of equity shares		
outstanding during the year	3,741,300	3741300
Profit/(loss) for the year	7,544,218	4286790
Nominal value of equity share (Rs.)	10	10
Basic and diluted EPS (Rs.)	2	1.15

^{20.} IND AS 21 EFFECTS OF CHANGES IN FOREIGN EXCHANGE RATES : Foreign currency transactions are accounted for at the rates prevailing on the date of transaction. Difference arising out of foreign exchange rates is dealt with in the Profit & Loss account. Current assets and current liabilities relating to foreign currency transactions remaining unsettled at the end of the year are translated at the closing rates and profit or loss arising there from, if any, is dealt with in the Profit & Loss account.

21. MANAGEMENT REMUNERATION :

Sr. No.	Particulars of remuneration	MD/WTD/Manager			Name of the Managerial Person other than MD/ WTD/Manager		Total Amount
		Alkesh Gosalia as Managing Director	Alkesh Gopani as a Managing Director *	Umang Gosalia as Whole Time Director	Keyur Vora as CFO	Yash Vora as CS	
1	Gross Salary	3,900,000	2,000,000	1,980,000	1,314,570	501,930	9,696,500
	a) Salary as per provisons contained in section 17(1) of Income tax Act , 1961	-	-	-	-	-	-
	b) Value of Perquisites u/s 17(2) of Income Tax Act , 1961	-	-	-	-	-	-
	c) Profits in lieu of salary under section 17(3) Income Tax Act, 1961	-	-	-	-	-	-
2	Stock Option	-	-	-	-	-	-
3	Sweat Equity	_	-	-	-	-	-
4	Commission	_	-	-	-	-	-
5	Any Other Benefits	_	-	-	-	-	-
	Total	3,900,000	2,000,000	1,980,000	1,314,570	501,930	9,696,500

* Mr. Alkesh Gopani has resigned from the post of Managing Director and Director w.e.f. 8th February, 2021

23. Payment to Auditors :

Auditors Remuneration	2020-2021	2019-2020
Audit Fees	90000	90000
Total	90000	90000

24. MISCELLANEOUS EXPENDITURE : In the current year, company have incurred Product Development Expenses for research and development of a product which is classified under Miscellaneous expenditure under non- current assets. Company have not charged any such miscellaneous Expenditure in the Profit and loss account of during the year.

25. Contingent Liabilities & Commitments:

Particulars	2020-2021	2019-2020
(i) Contingent Liabilities		
(a) Bank Guarantees issued by bank on behalf of Company for which company has issued counter guarantee	10,000,000	10,000,000
(ii) Commitments		
(a) Estimated amount of Contracts to be executed on capital account and not provided for	-	-

23. OTHER EXPLANATORY NOTES :

- i. The Company has not received any memorandum (as required to be filed by the suppliers with the notified authority under the Micro, Small and Medium Enterprises Development Act, 2006) claiming their status as on 31st March, 2021 as micro, small or medium enterprises. Consequently the amount paid/payable to these parties could not be ascertained. Hence no provision has been made in the books of accounts.
- ii. Balance with Parties are subject to reconciliation / confirmation with / by them. In absence of such confirmations, balances are as per books are taken and relied upon by the auditors.
- iii. Payments received / made through third parties are subject to confirmation.
- iv. Wherever any supporting are not made available in respect of any expenses / entries, the same is relied upon the information's and explanations given by the management to the auditors.
- v. Fixed Assets are stated as certified by the Management of the company. The Auditors neither verify the same nor were any details as to physical verification of the same made available to the Auditors
- vi. Previous Year's figure has been re-grouped/re-arranged wherever necessary.
- 24. Other Disclosures :
 - (A) Disclosures required under Section 22 of the Micro, Small and Medium Enterprises Development Act,2006:

The company is in the process of obtaining information regarding enterprises covered under Micro, Small and Medium Enterprises as per MSMED Act, 2006. However no information from any enterprise regarding above has been received by the company, and therefore no information is available with the company. The Company has not made any payment of Interest nor provided Interest payable if any on dues to suppliers.

For B A Shah S R Mehta & Co. Chartered Accountants	For Parmax Pharma Limited	
Firm Registration No.: 128796W	Dr. Umang Gosalia Managing Director DIN: 05153830	Ami Shah Director DIN: 08158605
Malay Shah Partner Membership No. 159526	Keyur Vora	Yash Vora
UDIN: 21159526AAAAAP8914 Date : 29.06.2021 Place : Rajkot	CFO Date : 29.06.2021 Place : Rajkot	Company Secretary

PARMAX PHARMA LIMITED

CIN: L24231GJ1994PLC023504

Registered Office: Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot – 360 311, Gujarat, India E-mail: info@parmaxpharma.com

ATTENDANCE SLIP

(To be handed over at the entrance of the meeting hall)

27th Annual General Meeting on Monday of 20th September, 2021


Name of Shareholder	
Address	
Ledger Folio No./DP Id/Client Id	
No. of shares held	
Name of Proxy	

I certify that I am the registered shareholder/proxy for the registered shareholder of the company

I hereby record my presence at the 27th Annual General Meeting held on the Monday, 20th September, 2021 at 2:00 p.m. at the registered office of the company at Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot – 360 311, Gujarat, India.

Signature of Shareholder/Proxy





* Route-map of venue for holding 25th Annual General Meeting of Parmax Pharma Limited



Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Rajkot 360311